PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 06 September 2000 (06.09.00)	
International application No. PCT/GB00/00219	**Applicant's or agent's file reference** WPP81798
International filing date (day/month/year) 24'January 2000 (24.01.00)	**Priority date** (day/month/year) 22 January 1999 (22.01.99)
Applicant MORGAN, James, Alun, Wynne et al	

1. The designated Office is hereby notified of its election made:

   [X] in the demand filed with the International Preliminary Examining Authority on:

   16 August 2000 (16.08.00)

   [ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

   [ ] was not

   made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Juan Cruz
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

TENT COOPERATION TREAT

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Notification of Transmittal of International Search Report
WPP81798	I ACTION	(Form PCT/ISA/220) as well as, where applicable, item 5 below.

International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/GB 00/ 00219	24/01/2000	22/01/1999

Applicant

Horticulture Research International et al

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of ____5____ sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

---

1. **Basis of the report**

   a. With regard to the **language**, the international search was carried out on the basis of the International application in the language in which it was filed, unless otherwise indicated under this item.

   [ ] the International search was carried out on the basis of a translation of the International application furnished to this Authority (Rule 23.1(b)).

   b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the International application, the International search was carried out on the basis of the sequence listing :

   [X] contained in the International application in written form.

   [ ] filed together with the International application in computer readable form.

   [ ] furnished subsequently to this Authority In written form.

   [X] furnished subsequently to this Authority In computer readble form.

   [X] the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the International application as filed has been furnished.

   [X] the statement that the Information recorded In computer readable form is identical to the written sequence listing has been furnished

2. [X] **Certain claims were found unsearchable** (See Box I).

3. [ ] **Unity of Invention is lacking** (see Box II).

4. With regard to the **title**,

   [ ] the text is approved as submitted by the applicant.

   [X] the text has been established by this Authority to read as follows:

   ## BIOLOGICAL CONTROL OF NEMATODES

5. With regard to the **abstract**,

   [X] the text is approved as submitted by the applicant.

   [ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.   1

   [X] as suggested by the applicant.   [ ] None of the figures.

   [ ] because the applicant failed to suggest a figure.

   [ ] because this figure better characterizes the Invention.

INTERNATIONAL SEARCH REPORT

B x I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark n Protest   ☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7   A01N63/00   A01N63/02   C12N15/31   C12P21/00   C07K14/24
//(C12P21/00,C12R1:01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7   A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 22598 A (UNIV READING ;ELAWAD SAMI ABDULRAHAMAN (GB); HAGUE NIGEL GRAHAM MA) 14 May 1999 (1999-05-14) cited in the application page 1 -page 2 page 4, line 7 - line 14 page 5, line 2 - line 8 page 5, line 25 - line 28 page 8, line 1 - line 15; claims 1-3,9,10,14; example 5 --- -/--	1-9,11, 29

[X] Further documents are listed in the continuation of box C.   [X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
16 May 2000	13/06/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Muellners, W

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X,P	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US AN 2000:109497, GREWAL, PARWINDER S. (1) ET AL: "Allelopathy: A possible mechanism of suppression of plant-parasitic nematodes by entomopathogenic nematodes." retrieved from STN XP002136524 abstract & NEMATOLOGY, (NOV., 1999) VOL. 1, NO. 7-8, PP. 735-743. , ---	1-9,11, 29
X,P	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US AN 2000:109391, HAN, RICHOU ET AL: "Trans - specific nematicidal activity of Photorhabdus luminescens." retrieved from STN XP002136525 abstract & NEMATOLOGY, (NOV., 1999) VOL. 1, NO. 7-8, PP. 687-693. , ---	1-9,11, 29
X,P	CHEMICAL ABSTRACTS, vol. 132, Columbus, Ohio, US; abstract no. 163304, HU, KAIJI ET AL: "Nematicidal metabolites produced by Photorhabdus luminescens (Enterobacteriaceae), bacterial symbiont of entomopathogenic nematodes" XP002136522 abstract & NEMATOLOGY (1999), 1(5), 457-469 , ---	1-9,11, 29
X,P	WO 99 42589 A (NOVARTIS ERFINDUNGEN VERWALTUN ;NOVARTIS AG (CH); KRAMER VANCE CAR) 26 August 1999 (1999-08-26) cited in the application page 1 -page 2, paragraph 3; claims ---	12-18
X	CHEMICAL ABSTRACTS, vol. 126, Columbus, Ohio, US; abstract no. 234686, GEORGIS, R. ET AL: "Novel pesticidal substances from the entomopathogenic nematode-bacterium complex" XP002136523 abstract & ACS SYMP. SER. (1997), 658(PHYTOCHEMICALS FOR PEST CONTROL), 134-143 , ---	1-9,11, 29

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	K. HU ET AL.: "Mortality of Plant-Parastic Nematodes Caused by Bacterial (Xenorhabdus spp. and Photorhabdus Luminescens) Culture Media" JOURNAL OF NEMATOLOGY, vol. 27, no. 4, December 1995 (1995-12), XP000905673 the whole document	1-9,11, 29
X	WO 98 08388 A (MORGAN JAMES ALUN WYNNE ;JARRETT PAUL (GB); ELLIS DEBORAH JUNE (GB) 5 March 1998 (1998-03-05) cited in the application page 1, line 4 - line 9 page 6, line 21 -page 9, line 9 page 11, line 10 -page 12, line 19; claims 17,18,21,23-25,29	6-9, 11-30
X	PATENT ABSTRACTS OF JAPAN vol. 013, no. 286 (C-613), 29 June 1989 (1989-06-29) -& JP 01 080294 A (SUMITOMO CHEM CO LTD;OTHERS: 01), 27 March 1989 (1989-03-27) abstract; figures 2-1	12-18
A	WO 92 19739 A (MYCOGEN CORP) 12 November 1992 (1992-11-12) cited in the application	1-30
X	page 1 -page 2, line 32; claims	12-18

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9922598	A	14-05-1999	AU	9753098 A	24-05-1999
WO 9942589	A	26-08-1999	AU	3028699 A	06-09-1999
WO 9808388	A	05-03-1998	AU	4024997 A	19-03-1998
			CN	1233938 A	03-11-1999
			EP	0923295 A	23-06-1999
			ZA	9707373 A	15-02-1999
JP 01080294	A	27-03-1989	JP	2117839 C	06-12-1996
			JP	8017707 B	28-02-1996
WO 9219739	A	12-11-1992	AU	667041 B	07-03-1996
			AU	2025292 A	21-12-1992
			AU	656726 B	16-02-1995
			AU	7826491 A	12-12-1991
			BR	9205969 A	26-07-1994
			CA	2042868 A	12-12-1991
			EP	0462721 A	27-12-1991
			EP	0517367 A	09-12-1992
			HU	62928 A	28-06-1993
			JP	4229170 A	18-08-1992
			NZ	242560 A	26-01-1994
			PL	290626 A	24-02-1992
			US	5439881 A	08-08-1995
			US	5753492 A	19-05-1998
			ZA	9203168 A	27-01-1993

PCT

D INTELLECTUAL PROPERTY ORGANIZATIOI
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) **International Patent Classification** [7] : A01N 63/00, 63/02, C12N 15/31, C12P 21/00, C07K 14/24 // (C12P 21/00, C12R 1:01) **A1**	(11) **International Publication Number:** WO 00/42855 (43) **International Publication Date:** 27 July 2000 (27.07.00)

(71) **Applicant** (for all designated States except US): HORTICUL-TURE RESEARCH INTERNATIONAL [GB/GB]; Welles-bourne, Warwick, Warwickshire CV35 9EF (GB).

(72) **Inventors; and**
(75) **Inventors/Applicants** (for US only): MORGAN, James, Alun, Wynne [GB/GB]; Horticulture Research International, Wellesbourne, Warwick, Warwickshire CV35 9EF (GB). JARRETT, Paul [GB/GB]; Horticulture Research International, Wellesbourne, Warwick, Warwickshire CV35 9EF (GB). ELLIS, Debbie [GB/GB]; Horticulture Research International, Wellesbourne, Warwick, Warwickshire CV35 9EF (GB). OUSLEY, Margaret, Anne [GB/GB]; Horticulture Research International, Wellesbourne, Warwick, Warwickshire CV35 9EF (GB).

(74) **Agent:** RUFFLES, Graham, Keith; Marks & Clerk, 57–60 Lincoln's Inn Fields, London WC2A 3LS (GB).

(54) **Title:** BIOLOGICAL CONTROL OF NEMATODES

(57) **Abstract**

Nematodes can be controlled through the use of bacteria associated symbiotically with an entomopathogenic nematode. The bacteria can be employed for nematode control, or engineered to a recombinant form. Control may be achieved using material such as a peptide. The peptide can be obtained from a natural or engineered nucleic acid.

BIOLOGICAL CONTROL OF NEMATODES

TECHNICAL FIELD

The present invention relates to methods and materials for controlling nematodes.

PRIOR ART

Several thousand species of nematodes, sometimes called eel worms, are known. Numerous nematodes attack and parasitize humans and animals and cause disease. Additionally, several hundred species are known to feed on living plants. Certain of these are reviewed by Agrios in "Plant Pathology - 3rd Ed" Pub Academic Press Inc, see Chapter 15 therein.

Methods of controlling nematodes and their associated diseases include cultural practices; biological methods, e.g. use of resistant varieties; physical methods, e.g. heat; and use of chemical agents.

Patent application WO 92/19739 (Mycogen) relates to genes and gene fragments from *Bacillus thuringiensis* which have nematocidal activity. These generally encode crystal toxins from particular strains.

Patent application EP 0 303 426 (Mycogen) also relates to strains of *B. thuringiensis* which have nematocidal activity.

Patent application EP 0 171 381 (Monsanto) relates to particular soil bacteria which are capable of proliferating in an environment which is infested with

2

nematodes such as pseudomonads which colonise the surface of plant roots. The basis for the controlling activity appears to stem from glycosidase enzymes which are hypothesised to directly inhibit the nematodes.

Notwithstanding these disclosures, there is an ongoing requirement for materials which have nematocidal activity, for instance for use in crop protection or nematode-mediated disease control.

Patent application PCT/WO 99/22598 (University of Reading) published 14 May 1999 claims a biopesticide for the control of insect pests or plant parasitic nematodes or both, which comprises as an effective agent a species of bacteria which is a symbiont of an entomopathogenic nematode.

DISCLOSURE OF THE INVENTION

The present inventors have established that species of bacteria which in nature are associated symbiotically with entomopathogenic nematodes, can in fact be utilised to control nematodes, and in preferred forms of the invention, to kill them. The bacteria themselves can be employed, or nematode control agents can be used which are derived from such bacteria. In one aspect of the invention, the present invention employs bacteria which are engineered and thus not naturally occurring, or nematode control agents which are derived from natural or non-natural bacteria.

It has been reported that certain bacterial species such as *Xenorhabdus* and *Photorhabdus* can be used to control insects, see e.g. PCT/WO 98/08388 of MAFF, PCT/WO 97/17432 of WARF, and PCT/WO 99/42589 of Novartis. An effect against nematodes had not previously been demonstrated.

The symbiotic bacteria used in the present invention are isolatable from nematodes or the insects which the nematodes attack, and differ fundamentally in terms of life-style and activity from those soil bacteria such as *B. thuringiensis* or pseudomonads which have previously been suggested as being nematocidal.

Indeed, *prima facie*, it seems highly unlikely that nematode symbiotes might possess nematocidal activity. However, in the light of the present disclosure, a number of possible explanations for the observed activity can be tentatively proposed. Firstly, in order to protect a nutrient supply from a dead insect, the bacteria might produce anti-nematocides to prevent saprophytic nematodes gaining access. Alternatively, to become a symbiont, the bacterial strains may have once been pathogens of these nematodes and evolved towards a less hostile symbiotic relationship. The nematocidal activity may be an evolutionary throwback from the original pathogenic relationship, in which case it may be expected to be widely present amongst bacteria which have evolved in this way.

A first aspect of the present invention is the use of bacterial strains to control a target nematode, characterised in that in nature the bacterial strain is associated symbiotically with an entomopathogenic nematode.

As discussed in more detail below, the bacterial strains may be used in the methods of the present invention *per se*, or they may be used as a source of nematode control agent. The nematode control agent can be derived directly, or be prepared and utilised through recombinant DNA techniques, optionally via a host cell.

The target nematode will generally be different to the nematode with which the bacterial strain is found symbiotically in nature.

4

By means of the present invention employing bacteria or a nematode control agent, it becomes possible to control nematodes, in the sense of, to prevent or retard the effect that the nematode has on other organisms such as animals or more preferably plants, or to reduce the number of nematodes or nematode eggs in an area of interest, or to alleviate or cure a disease caused by nematodes. Control may be at the level of larval nematodes or nematode eggs, or may inhibit the motion, feeding or infectivity of adult nematodes. Nematocidal control may be employed to kill the nematode target. Such controlling activity can be assessed as shown in the Examples below.

PREFERRED EMBODIMENTS

The present invention provides a composition for the control of parasitic nematodes which comprises as an effective agent a species of bacteria which is a symbiont of an entomopathogenic nematode, or engineered bacteria having such activity, or a nematode control agent derived from natural or engineered bacteria.

Correspondingly, the present invention also provides a method of nematode control employing such a composition.

The bacterial species is typically of the genera *Xenorhabdus* or *Photorhabdus*, preferably the genus *Xenorhabdus*, for instance the species *Xenorhabdus bovienii*. Examples of particularly preferred bacteria include:

Xenorhabdus bovienii strain H31 deposited with NCIMB under accession number NCIMB 40985 on 20 January 1999;

Xenorhabdus bovienii strain I73 deposited with NCIMB under accession number NCIMB 40986 on 05 November 1998; and

Xenorhabdus strain C42 deposited with NCIMB under accession
number NCIMB 41004 on 05 November 1998.

The nematode control agent can be a peptide derived from a symbiont of an
entomopathogenic nematode or an engineered bacterium has functional
activity against a nematode.   The peptide nematode control agent can be
produced from a nucleic acid derived from a symbiont of an entomopath
nematode or an engineered bacterium and which encodes such a peptide.
The peptide can be an oligopeptide or a polypeptide, notably a protein.   In
one version, the nematode control agent is a toxin with toxic activity against
nematodes, but the nematode control agent can have other activity.

The nucleic acids of this invention can be employed in a method of producing
a peptide comprising the step of causing or allowing the expression from a
nucleic acid of this invention in a suitable host cell.

The nucleic acid can comprise a natural nucleotide sequence or a
degeneratively equivalent sequence, and functional variants thereof.
Variants include homologous variants encoding a peptide which is a
nematode control agent, the nucleic acid having 70% or more DNA sequence
identity and/or the peptide having 70% or more amino acid sequence
identity.   Especially preferred nucleic acids in p 13-1f and p 14-2f and
variants thereof.

The present invention extends to nucleic acids having a sequence which is a
derivative by way of addition, insertion, deletion or substitution of one or
more nucleotides.   The nucleic acid can contain longer expressed sequences
such that the nematode control agent is expressed as a fusion protein.

Nucleic acids complementary to the nucleic acid encoding a nematode

6

control agent are also part of this invention.

Nucleic acids for use as a probe or primer having a nucleotide sequence of at least 15, 18, 21, 24 or 30 nucleotides, which sequence is present in, or complementary to, the nucleic acid encoding nematode control agent are further provided by this invention. In this respect, the invention extends to a method for identifying or cloning a nucleic acid for nematode control agent which method employs such a nucleic acid probe.

A method provided by this invention comprises the steps of:

(a)   providing a preparation of nucleic acid from a bacterium,

(b)   providing a probe,

(c)   contacting nucleic acid in said preparation with said probe under conditions for hybridisation of probe to any said gene or homologue in said preparation, and,

(d)   identifying said gene or homologue if present by its hybridisation with said probe.

The hybridisation conditions can be selected to allow the identification of sequences having 70% or more sequence identity with the probe.

In one embodiment, the method comprises use of two primers to amplify a nucleic acid encoding a nematode control agent, at least one of the primers having a conserved nucleotide sequence of at least 15 nucleotides.

A method is further made possible by this invention comprising the steps of:

(a)   providing a preparation of nucleic acid from a bacterium,

(b)   providing a pair of nucleic acid molecule primers, at least one of which is a primer,

(c)   contacting nucleic acid in said preparation with said primers under

SUBSTITUTE SHEET (RULE 26)

conditions for performance of PCR,

(d)   performing PCR and determining the presence of absence of an amplified PCR product.

Additionally, the invention provides a recombinant vector comprising a nucleic acid of this invention.   The vector is preferably capable of replicating in a suitable host such as *E. coli* or in *Xenorhabdus*.   The vector can be a baculovirus.   In a preferred feature, the nucleic acid is operably linked to a promoter or other regulatory element for transcription in a host cell. Vectors can further comprise any one or more of the following: a terminator sequence; a polyadenylation sequence; an enhancer sequence; a marker gene; a sequence encoding pesticidal material derived from *Bacillus thuringiensis*.

The vector can be a plant vector.

The vector of this invention can be introduced into a cell.   Thus, a method for transforming a plant cell comprises the step of causing or allowing recombination between the vector and the plant cell genome to introduce the nucleic acid into the genome.   The nucleic acid can be incorporated into chloroplast DNA, or into mitochondrial DNA.

Host cells comprising a vector are also part of this invention.   The host cell can be a plant cell, which may be in a plant.

To this end, a method for producing a transgenic plant comprises the step of regenerating a plant from the transformed cell.   In turn, plants of this invention extend to the progeny of such plants.

Examples of plants of this invention include crop species which can be

8

protected, notably maize, cotton, soya, rice, *Brassica* species, tomato, potato, sugar beet, barley, soybean, peanut, onion, rye, wheat, corn, banana, raspberry, bean.   Decorative and other plants are also possible, e.g. rose.

A part of the propagule of the plants is also envisaged by this invention.

A method of influencing or affecting the toxicity of a cell such as a plant cell is provided where the method includes causing or allowing expression of a heterologous nucleic acid of this invention within the cells.

In a further aspect, the invention involves the use of a material selected from: an *X. bovienii* strain, a nematode control agent; a nucleic acid; a host cell; a plant; a peptide; or a composition of the invention, for the control of a pest, especially where the pest is a nematode and the material is used to control the nematode.

The present invention extends to control of helminthiasis in humans and other animals including domesticated animals such as swine, sheep, horses, cattle, goats, dogs, cats and poultry.   The nematodes to be controlled include *Haemonchus, Trichostrongylus, Ostertagia, Nematodirus, Cooperia, Ascaris, Bunostomum, Oesophagosromuni, Chaberria, Trichuris, Strongylus, Trichonema, Dictyocaulus, Capillaria, Heterkis, Toxocara, Ascaridia, Oxyuris, Ancylostoma, Uncinaria, Toxascaris, Caenorhabditis* and *Parascaris*.

Target nematodes may be selected from the genera *Aphelenochoides, Anguina, Bursaphalenchus, Criconemella, Melodigyne, Ditylenchus, Globodera, Heliocotylenchus, Heterodera, Pratylenchus, Radopholus, Rotelynchus, Tylenchus, Trichodorus, Xiphenema,* and *Caenorhabditis*.

The compositions of this invention can be used in conjunction with *Bacillus*

thuringiensis or pesticidal materials derived therefrom.

In a further aspect, there is provided an antibody or fragment thereof, or a polypeptide comprising the antigen-binding domain of the antibody, capable of specifically binding a peptide of this invention.

Such an antibody or fragment can be obtained by immunising a mammal with the peptide, and is useful in a method of identifying and/or isolating a nematode control agent comprising the step of screening candidate polypeptides with a polypeptide comprising the antigen-binding domain of the antibody of claim.

Some further aspects of preferred embodiments of the invention will now be discussed.

Bacterial strains

These can be derived from any entomopathogenic nematode. Preferred species are *Xenorhabdus* and *Photorhabdus*.

Potential sources of bacteria for use in the methods of the present invention may be identified by any preferred method. For instance, entomopathogenic nematodes can be isolated using an insect baiting technique such as that described by Bedding & Akhurst (1975) Nematologia 21: 215-227. Bacteria from nematodes identified as being pathogenic to the insect are isolated, cultured, and used as a source of nematocidal agent, e.g. by analogy with the methods used in the Examples below. Preferably *Xenorhabdus* or *Photorhabdus* species are used.

The preferred bacterial strains include ones which have the characteristics of

strain C42, I73 or H31 isolated by the present inventors. This *Xenorhabdus* strain has the following characteristics: rod shaped; motile; non-bio luminescent; blue on NBTA; produces antibiotics; resistant to ampicillin; forms circular colonies; has convex morphology; white colour.

This strain was presumptively identified as belonging to the genera *Xenorhabdus* since it was isolated from an insect killed by an entomopathogenic nematode and had the above characteristics. The strain has been deposited at the NCIMB (23 St Machar Drive, Aberdeen, AB24 3RY, Scotland) by the applicants under accession number NCIMB 41004 on 20 January 1999.

Further preferred strains of the present invention are two strains of *X. bovienii* designated H31 and I73 which have also been deposited under the terms of the Budapest Treaty at the NCIMB under the accession numbers NCIMB 40985 and 40986 respectively. These share characteristics of C42 in that they are rod-shaped; motile; non-bioluminescent; blue on NBTA; produce antibiotics; resistant to ampicillin; form circular colonies; and have convex morphology. The strains were identified as belonging to the species *X. bovienii* when compared to the *X. bovienii* type strain T228 using Restriction Analysis of the complete 16S rRNA gene and partial sequence analysis.

Target nematodes and diseases

The group of diseases described generally as helminthiasis is due to infection of an human or other animal host with parasitic worms known as helminths. Helminthiasis is a prevalent and serious economic problem in domesticated animals such as swine, sheep, horses, cattle, goats, dogs, cats and poultry. Among the helminths, the group of worms described as nematodes causes

widespread and often at times serious infection in various species of animals. The most common genera of nematodes infecting the animals referred to above are *Haemonchus, Trichostrongylus, Ostertagia, Nematodirus, Cooperia, Ascaris, Bunostomum, Oesophagosromuni, Chaberria, Trichuris, Strongylus, Trichonema, Dictyocaulus, Capillaria, Heterakis, Toxocara, Ascaridia, Oxyuris, Ancylostoma, Uncinaria, Toxascaris, Caenorhabditis* and *Parascaris*. Certain of these, such as *Nematodirus, Cooperia,* and *Oesophagostomum*, attack primarily the intestinal tract, while others, such as *Dictyocaulus* are found in the lungs. Still other parasites may be located in other tissues and organs of the body.

The bacteria and encoded toxins of the invention may be used as nematocides for the control of the nematodes and diseases discussed above. More preferably, however, they are used to control soil and plant parasitic nematodes. Particular crop species which can be protected include tomatoes, potatoes, sugar beet, barley, soybean, peanut, onion, rye, wheat, corn, banana, raspberry, beans. Decorative and other plants may also be treated e.g. rose.

Target nematodes may be selected from the genera Aphelenochoides, *Anguina, Bursaphalenchus, Criconemella, Melodoigyne, Ditylenchus, Globodera, Helicotylenchus, Heterodera, Pratylenchus, Radopholus, Rotelynchus, Tylenchus, Trichodorus, Xiphenema*. A further organism used in certain of the Examples below is *Caenorhabditis elegans*. Other target organisms and plants are discussed by Agrios in "Plant Pathology - 3rd Ed" Pub Academic Press Inc, see Chapter 15 therein.

As stated above, the target nematode will generally be different to that with which the bacterial strain is found in nature.

Methods of use of bacteria

The bacteria may be used in any appropriate method which brings them into contact with the target nematode, preferably such that they, or their products, are ingested or absorbed by the target nematode.

In particular, regarding plants, the bacteria may be formulated in a variety of ways so as to enhance stability. For instance they may be employed in admixture with substrates to protect the cells.

The mixture can be spread over, ploughed into or otherwise mixed with nematode infected or potentially infected soil.

Regarding animals, bacteria intended for enteric inoculation can be mixed with carrier material that is suitable for ingestion by the intended animals.

Isolation of agent

Nematode control agents of the present invention, which may be proteinaceous, or nucleic acids encoding them, may be isolated and/or purified from the C42, I73 or H31 bacteria described above, in substantially pure or homogeneous form, or free or substantially free of other materials from the bacterial strain of origin. Where used herein, the term "isolated" encompasses all of these possibilities.

Methods of purifying proteins from heterogenous mixtures are well known in the art, e.g. selective precipitation, proteolysis, ultrafiltration with known molecular weight cut-off filters, ion-exchange chromatography, gel filtration, etc. A particularly useful initial technique in this regard is ultracentrifugation. Further methods which are known to be suitable for

13

protein purification are disclosed in "Methods in Enzymology Vol 182 - Guide to Protein Purification" Ed. M P Deutscher, Pub. Academic Press Inc.   Other references which outline techniques commonly used by those of ordinary skill in the art include "Protein Purification - principles and practice" Pub. Springer-Verlag, New York Inc (1982), and by Harris & Angal (1989) "Protein purification methods - a practical approach " Pub. O.U.P. UK.

Nematocidal activity may be assessed using a spread assay as discussed below.

The C42, I73 or H31 agent may be wholly or partially synthetic. In particular they may be recombinantly produced from nucleic acid sequences which are not found together in nature (do not run contiguously) but which have been ligated or otherwise combined artificially.

For instance, in the Examples below, nucleic acid encoding toxin(s) from I73 has been expressed in hosts cells using a vector system.   Amino acid sequences of 38 different putative I73 toxin(s) are set out in sequence Annex I.   These sequences are based on the nucleic acid sequence set out in Fig 2 ('chrim5'), a cosmid clone derived from I73 genomic DNA which conferred nematocidal activity upon *E. coli* cells into which it was introduced (i.e. significantly reduced nematode larval growth and development, and feeding). As detailed below, the entire amino acid sequence as set out in each case may not be required for nematocidal activity.   In particular the portion up to the first Met in each sequence may be omitted, as may other portions which may not contribute to the nematocidal activity.   Thus, not all the proteins or genes may be required for nematocidal activity, and usually there will be one or more principal proteins, though others may play supporting roles such as in enhancing the activity or encoding other nematocidal activities.

14

Thus isolated nematocidal agents comprising a polypeptide containing all, or a nematocidal fragment, of any of the depicted I73 sequences, form one aspect of the present invention. Preferred agents include those encoded by p14-2f and p13-1f. Other active variants of these sequences are also encompassed as described below.

Candidate agents for use in this invention to control nematodes extend to those from the bacteria described in PCT/WO 99/22598, as well as the insecticidal toxins and bacteria of PCT/WO 99/42589, PCT/WO 98/08388 and PCT/WO 97/17432, the disclosures of which are incorporated by reference.

Nucleic acids and variants

In one aspect of the present invention there is provided a nucleic acid molecule encoding a nematode control agent of the present invention, for example a toxin, as described above.

The nucleic acid may be derived from the sequence shown in Fig 2 or the complement (or degenerate equivalent) thereof. This sequence (cHRIM5) was itself derived from I73 and identified by its unexpected nematocidal activity. Regions of this sequence believed to correspond to genes of the present invention are described in Fig 3. Isolated nucleic acids comprising one or more of these regions which encode a nematocidal activity are particularly preferred.

In the light of the present disclosure, further nucleic acids of the present invention may be isolated using PCR or southern blotting or other techniques well known to those skilled in the art. This requires the use of two primers to specifically amplify target nucleic acid, so preferably two

nucleic acid molecules with sequences characteristic of the C42, H31 or

most preferably an I73 toxin isolated as above are employed. Using RACE

PCR, only one such primer may be needed (see "PCR protocols; A Guide to

Methods and Applications", Eds. Innis et al, Academic Press, New York,

(1990)).

Thus a method involving use of PCR in obtaining nucleic acid according to

the present invention may include:

(a) providing a preparation of bacterial nucleic acid,

(b) providing a pair of nucleic acid molecule primers suitable for PCR, at least

one of said primers being a primer based on a toxin from C42, H31 or I73,

(c) contacting nucleic acid in said preparation with said primers under

conditions for performance of PCR,

(d) performing PCR and determining the presence or absence of an amplified

PCR product. The presence of an amplified PCR product may indicate

identification of a variant.

In a further aspect of the present invention there are disclosed nucleic acids

which are variants of the C42, I73 or H31 toxin. A variant nucleic acid

molecule shares homology (or identity) with all or part of the C42, H31, or

most preferably I73 sequence discussed above.

Preferably sequence comparisons are made using FASTA and FASTP (see

Pearson & Lipman, 1988. Methods in Enzymology 183: 63-98). Parameters

are set, using the default matrix blosum62, as follows:

Gapopen (penalty for the first residue in a gap): -12 for proteins / -16 for

DNA

Gapext (penalty for additional residues in a gap): -2 for proteins / -4 for DNA

KTUP word length: 2 for proteins / 6 for DNA.

16

Homology (similarity or identity) may be at the nucleotide sequence and/or encoded amino acid sequence level. Preferably, the nucleic acid and/or amino acid sequence shares at least about 70%, 75%, 80%, or 85% homology, most preferably at least about 90%, 95%, 96%, 97%, 98% or 99% homology.

Another method for assessing homology at the nucleic acid level is by hybridization screening. One common formula for calculating the stringency conditions required to achieve hybridisation between nucleic acid molecules of a specified sequence homology is shown in Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al, 1989, Cold Spring Harbor Laboratory Press:

$Tm = 81.5°C + 16.6Log [Na+] + 0.41 (\% G+C) - 0.63 (\% formamide) - 600/\#bp$ in duplex

As an illustration of the above formula, using [Na+] = [0.368] and 50-% formamide, with GC content of 42% and an average probe size of 200 bases, the Tm is 57°C. The Tm of a DNA duplex decreases by 1 - 1.5°C with every 1% decrease in homology. Thus, targets with greater than about 75% sequence identity would be observed using a hybridization temperature of 42°C. Such a sequence would be considered substantially homologous to the nucleic acid sequence of the present invention.

Variants of the present invention can be artificial nucleic acids. Alternatively they may be novel, naturally occurring, nucleic acids, isolatable using the information disclosed herein. Thus a variant may be a distinctive part or fragment (however produced) corresponding to a portion of the C42, I73 or H31 toxin. The fragments may encode particular functional parts of the agent or they may be used for probing for, or amplifying, sequences corresponding to C42, I73 or H31 toxin. Sequence variants which occur naturally may include homologs of the C42, I73 or H31 toxin from other

17

bacteria, including nematode-symbionts. Artificial variants (derivatives) may be prepared by those skilled in the art, for instance by site directed or random mutagenesis (i.e. nucleotide addition, deletion or substitution, optionally to lead to amino acid addition, deletion or substitution) or by direct synthesis. Preferably the variant nucleic acid is generated either directly or indirectly from an original nucleic acid encoding the C42, I73 or H31 toxin.

Changes may be desirable for a number of reasons, including introducing or removing the following features. Sites which are required for pre- or post-translation modification. Changes for codon usage preferences to enhance gene expression in different organisms. Leader or other targeting sequences (e.g. membrane or golgi locating sequences) may be added to the expressed protein to determine its location following expression. All of these may assist in efficiently cloning and expressing an active polypeptide in recombinant form. Other desirable mutation may be random or site directed mutagenesis in order to alter the activity (e.g. host specificity) or stability of the encoded polypeptide. Changes may be by way of conservative variation, i.e. substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine. Also included are active (nematocidal) variants having non-conservative substitutions.

Variant nucleic acids encompass all of these possibilities. When used in the context of polypeptides or proteins they indicate the encoded expression product of the variant nucleic acid i.e. variants of C42, I73 or H31 toxin e.g. variants of the I73 toxin sequences disclosed hereinafter.

Vectors and production of host cells

18

In one aspect of the present invention, the nucleic acid encoding the nematode control agent is provided in the form of a recombinant and preferably replicable vector.

Generally speaking, those skilled in the art are well able to construct vectors and design protocols for recombinant gene expression. Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. For further details see, for example, Sambrook et al (1989) *supra.*

The permitted vectors include, *inter alia,* any plasmid, cosmid, phage or *Agrobacterium* binary vector in double or single stranded linear or circular form which may or may not be self transmissible or mobilizable, and which can transform a prokaryotic or eukaryotic host either by integration into the cellular genome or exist extrachromosomally, e.g. an autonomous replicating plasmid with an origin of replication. Illustratively integration can occur into chloroplast DNA or into mitochondrial DNA.

Preferably the nucleic acid in the vector is under the control of, and operably linked to, an appropriate optionally inducible promoter or other regulatory elements for transcription in a host cell such as a microbial, e.g. bacterial, yeast, filamentous fungal or plant cell. The vector may be a bi-functional expression vector which functions in multiple hosts. In the case of genomic DNA, this may contain its own promoter or other regulatory elements and in the case of cDNA this may be under the control of an appropriate promoter or other regulatory elements for expression in the host cell. The vectors and host cells into which they are introduced may be used to clone or otherwise

identify nucleic acids according to the invention.

The agent may be used as part of a viral vector which is itself pathogenic to nematodes.

Also of interest in the present context are nucleic acid constructs which operate as plant vectors. Specific procedures and vectors previously used with wide success upon plants are described by Guerineau and Mullineaux (1993) (Plant transformation and expression vectors. In: Plant Molecular Biology Labfax (Croy RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148). Suitable vectors may include plant viral-derived vectors (see e.g. EP-A-194809). Suitable promoters which operate in plants include the Cauliflower Mosaic Virus 35S (CaMV 35S). Other examples are disclosed at page 120 of Lindsey & Jones (1989) "Plant Biotechnology in Agriculture" Pub. OU Press, Milton Keynes, UK.

Host cells

The toxin genes or gene fragments encoding the nematocidal agents of the subject invention may be introduced into a host cell, microbial, animal or plant. Expression of the toxin gene in the host cell results, directly or indirectly, in the intracellular production and maintenance of the nematocide.

Thus the present invention also provides methods comprising introduction of such a construct into a plant cell or a microbial cell and/or induction of expression of a construct within a cell, by application of a suitable stimulus e.g. an effective exogenous inducer.

Hosts may be used to assay the activity of particular sequences or

20

fragments.   Hosts can also be used to generate quantities of toxin which can be employed in situ in suitable treated cells, or alternatively with suitable hosts, e.g., *Pseudomonas* viable microbes can be applied to the sites of nematodes where they will proliferate and where they or their products can be ingested by the nematodes.   Higher organisms, preferably plants, can also be engineered with the toxin. The result in each case is a control of the nematodes.   A host may be selected that can tolerate harsh environmental conditions and then grow when they improve, as illustrated by *Bacillus* species where the spores can exist under environmental extremes.

Characteristics of interest for use as a nematocide microcapsule i.e. a vehicle for the active agent include protective qualities for the nematocide, such as thick cell walls, pigmentation, and intracellular packaging or formation of inclusion bodies; leaf affinity; lack of mammalian toxicity; attractiveness to nematodes for ingestion; ease of killing and fixing without damage to the toxin; and the like.

Treated host cells

Where the cell is treated, the cell will usually be intact and be substantially proliferative form when treated, rather than in a spore form, although in some instances spores may be employed.   Treatment of the microbial cell, e.g. a microbe containing the bacterial toxin gene or gene fragment, can be by chemical or physical means, or by a combination of chemical and/or physical means, so long as the technique does not deleteriously affect the properties of the toxin, nor diminish the cellular capability in protecting the toxin.

Viable hosts

Where the toxin gene or gene fragment is introduced via a suitable vector into a microbial host, and said host is applied to the environment in a living state, it is preferable that microorganism hosts are selected which are known to occupy the phytosphere (phylloplane, phyllosphere, rhizosphere, and/or rhizoplane) of one or more crops of interest.   These microorganisms are selected so as to be capable of successfully competing in the particular environment (crop and other insect habitats) with the wild-type microorganisms, provide for stable maintenance and expression of the gene expressing the polypeptide pesticide, and, desirably, provide for improved protection of the nematocide from environmental degradation and inactivation.

A large number of microorganisms are known to inhabit the phylloplane (the surface of the plant leaves) and/or the rhizosphere (the soil surrounding plant roots) of a wide variety of important crops. These microorganisms include bacteria, algae, and fungi. Of particular interest are microorganisms, such as bacteria, e.g., genera *Pseudomonas*, *Erwinia*, *Serratia*, *Klebsiella*, *Xanthomonas*, *Streptomyces*, *Rhizobium*, *Rhodopseudomonas*, *Methylophilius*, *Agrobacterium* , *Acetobacter*, *Lactobacillus*, *Arthrobacter*, *Azotobacter*, *Leuconosroc*, and *Alcaligenes*; fungi, particularly yeast, e.g., genera *Saccharomyces*, *Cryprococcus*, *Kluyveromyces*, *Sporobolomyces*, *Rhodororula*, and *Aureobasidium*.

Plants as hosts

Nucleic acid encoding the nematocides of the present invention can be introduced into plant cells using any suitable technology, such as a disarmed Ti-plasmid vector carried by *Agrobacterium* exploiting its natural gene transfer ability (EP-A-270355, EP-A-0116718, NAR 12(22) 8711 - 87215 1984), particle or microprojectile bombardment (US 5100792, EP-A-444882,

22

EP-A-434616) microinjection (WO 92/09696, WO 94/00583, EP 331083, EP 175966, Green et al. (1987) Plant Tissue and Cell Culture, Academic Press), electroporation (EP 290395, WO 8706614 Gelvin Debeyser) other forms of direct DNA uptake (DE 4005152, WO 9012096, US 4684611), liposome mediated DNA uptake (e.g. Freeman et al. Plant Cell Physiol. 29: 1353 (1984)), or the vortexing method (e.g. Kindle, PNAS U.S.A. 87: 1228 (1990d). Physical methods for the transformation of plant cells are reviewed in Oard, 1991, Biotech. Adv. 9: 1-11.

Agrobacterium transformation is widely used by those skilled in the art to transform dicotyledonous species. It has also been used with filamentous fungi (see de Groot et al, 1998, Nature Biotechnology 16: 839-842).

Recently, there has also been substantial progress towards the routine production of stable, fertile transgenic plants in almost all economically relevant monocot plants (see e.g. Hiei et al. (1994) The Plant Journal 6, 271-282)). Microprojectile bombardment, electroporation and direct DNA uptake are preferred where *Agrobacterium* alone is inefficient or ineffective. Alternatively, a combination of different techniques may be employed to enhance the efficiency of the transformation process, e.g. bombardment with *Agrobacterium* coated microparticles (EP-A-486234) or microprojectile bombardment to induce wounding followed by co-cultivation with *Agrobacterium* (EP-A-486233).

Generally speaking, following transformation, a plant may be regenerated, e.g. from single cells, callus tissue or leaf discs, as is standard in the art. Almost any plant can be entirely regenerated from cells, tissues and organs of the plant. Available techniques are reviewed in Vasil et al., Cell Culture and Somatic Cell Genetics of Plants, Vol I, II and III, Laboratory Procedures and Their Applications, Academic Press, 1984, and Weissbach and

Weissbach, Methods for Plant Molecular Biology, Academic Press, 1989.

The generation of fertile transgenic plants has been achieved in the cereals rice, maize, wheat, oat, and barley (reviewed in Shimamoto, K. (1994) Current Opinion in Biotechnology 5, 158-162.; Vasil, et al. (1992) Bio/Technology 10, 667-674; Vain et al., 1995, Biotechnology Advances 13 (4): 653-671; Vasil, 1996, Nature Biotechnology 14 page 702).

Combination nematocides

In further embodiments of the invention, bacteria associated with entomopathogenic nematodes or the toxins or products discussed above are used in conjunction with other nematocidal bacteria such as *B. thuringiensis* strains (e.g. from WO 92/19739) or pesticidal materials derived therefrom.

Materials for use in the present invention

The present invention also embraces materials for use in the methods above. These materials include the novel bacterial strains which are associated symbiotically with an entomopathogenic nematode and which are capable of controlling a target nematode.   In particular the invention encompasses strain C42, I73 or H31 in isolated or substantially isolated form, or strains having the characteristics of C42, I73 or H31 (including nematocidal activity assessed as below).

Also embraced are compositions and formulations of these bacteria.   These may comprise or consist of wettable powders, granules or dusts, mixed with various inert materials, such as inorganic minerals (phyllosilicates, carbonates, sulfates, phosphates, methylcellulose, xanthan gum and the like) or botanical materials (powdered corncobs, rice hulls, walnut shells,

24

peat moss, vermiculite, soil, seeds, other plant tissue and the like). The formulations may include spreader-sticker adjutants, stabilizing agents or surfactants. Liquid formulations may be aqueous-based or non-aqueous and employed as foams, gels, suspensions, emulsifiable concentrates, or the like. The ingredients may include rheological agents, surfactants, emulsifiers, dispersants, or polymers.

Bacteria may be mixed with other material while in freeze-dried form, encapsulated in biodegradable or water-soluble material, or otherwise treated to prolong their viability or decrease their levels of metabolic activity during handling. If desired, the carrier material may contain assimilatable nutrient sources to support proliferation of the bacteria.

Also included are purified or substantially purified nematocidal agents (particularly proteinaceous agents) isolated or isolatable from the strains or host cells discussed above.

Thus the invention further discloses nematocidal compositions comprising one or more agents as described above. Such compositions preferably further comprise other nematocidal materials from other *Xenorhabdus* species or non-*Xenorhabdus* species. These other materials may be chosen such as to have complementary properties to the agents described above, or act synergistically with it.

Toxins of the invention for use with animals can be adapted to be administered orally in a unit dosage form such as a capsule, bolus or tablet, or as a liquid drench when used as an anthelmintic in mammals, and in the soil to control plant nematodes. The drench is normally a solution, suspension or dispersion of the active ingredient, usually in water, together with a suspending agent such as bentonite and a wetting agent or like

25

excipient.   Generally, the drenches also contain an antifoaming agent. Drench formulations generally contain from about 0.001 to 0.5% by weight of the active compound.   Preferred drench formulations may contain from 0.01 to 0.1% by weight, the capsules and boluses comprise the active ingredient admixed with a carrier vehicle such as starch, talc, magnesium stearate, or dicalcium phosphate.   Where it is desired to administer the toxin compounds in a dry, solid unit dosage form, capsules, boluses or tablets containing the desired amount of active compound usually are employed.   These dosage forms are prepared by intimately and uniformly mixing the active ingredient with suitable finely divided diluents, fillers, disintegrating agents and/or binders such as starch, lactose, talc, magnesium stearate, vegetable gums and the like.   Such unit dosage formulations may be varied widely with respect to their total weight and content of the antiparasitic agent, depending upon the factors such as the type of host animal to be treated, the severity and type of infection and the weight of the host.

When the active compound is to be administered via an animal feedstuff, it is intimately dispersed in the feed or used as a top dressing or in the form of pellets which may then be added to the finished feed or, optionally, fed separately.   Preferably, a carrier for feed administration is one that is, or may be, an ingredient of the animal ration.   Suitable compositions include feed premixes or supplements in which the active ingredient is present in relatively large amounts and which are suitable for direct feeding to the animal or for addition to the feed either directly or after an intermediate dilution or blending step.   Typical carriers or diluents suitable for such compositions include, for example, distillers' dried grains, corn meal, citrus meal, fermentation residues, ground oyster shells, wheat shorts, molasses solubles, corn cob meal, edible bean mill feed, soya grits, crushed limestone and the like.

Alternatively, the antiparasitic compounds may be administered to animals parenterally, for example, by intraluminal, intramuscular, intratracheal, or subcutaneous injection, in which event the active ingredient is dissolved or dispersed in a liquid carrier vehicle. For parenteral administration, the active material is suitably admixed with an acceptable vehicle, preferably of the vegetable oil variety, such as peanut oil, cotton seed oil and the like. Other parenteral vehicles, such as organic preparations using solketal, glycerol, formal and aqueous parenteral formulations, are also used. The active compound or compounds are dissolved or suspended in the parenteral formulation for administration; such formulations generally contain from 0.005 to 5% by weight of the active compound.

Further aspects of the invention include nucleic acids, vectors and host cells containing a heterologous construct according to the present invention, especially a plant or a microbial cell.

Such microbial cells may be treated as described in the methods above. Examples of chemical reagents are halogenating agents. Other suitable techniques include treatment with aldehydes, such as formaldehyde and glutaraldehyde; anti-invectives, such as zephiran chloride and cetylpyridinium chloride; alcohols, such as isopropyl and ethanol; various histologic fixatives, such as Bouin's fixative and Helly's fixative (See: Humason, Gretchen L., Animal Tissue Techniques, W.H. Freeman and Company, 1967); or a combination of physical (heat) and chemical agents that preserve and prolong the activity of the toxin produced in the cell when the cell is administered to the host animal. The method of inactivation or killing retains at least a substantial portion of the bio-availability or bioactivity of the nematode control agent.

27

In all of the compositions discussed above, the nematocide concentration may vary widely depending upon the nature of the particular formulation, particularly whether it is a concentrate or to be used directly. The nematocide will be present in at least 1% by weight and may be 100% by weight. The dry formulations will have from about 1-95% by weight of the nematocide while the liquid formulations will generally be from about 16% by weight of the solids in the liquid phase. The formulations will generally have from about 10^2 to about 10^{10} cells/mg, more preferably 10^7 to about 10^9 cells/mg. These formulations will be administered at about 50 mg (liquid or dry) to 1 kg or more per hectare. The formulations can be applied to the environment of the nematodes, e.g., plants, soil or water, by spraying, dusting, sprinkling, or the like.

In addition to the above the invention includes plant cells which have been transformed with the genes of the present invention, and plants which include such plant cells.

EXAMPLES OF THE INVENTION

The invention will now be further described with reference to the following non-limiting Figures and Examples. Other embodiments of the invention will occur to those skilled in the art in the light of these.

FIGURES

Fig 1 shows the cHRIM5 cosmid vector and subclones used for sequencing, as described in Example 6.

Fig 2 shows the sequence of cHRIM5 (1-37544 bps).

Fig 3 shows the position and orientation of ORFs in the cHRIM5 sequence.

Fig 4 shows deletions of cHRIM5 tested for nematocidal activity.

Fig 5 illustrates cloning of nematocidal activity in PLEX.

Example 1 - Source of strains C42, I73 and H31

Strain C42 was obtained using an insect entrapment method.   Insects
which were killed on the surface of a soil sample were observed under a
microscope at high magnification.   Any that contained high numbers of
bacteria and not fungal hyphae were presumed to have been killed by insect
parasitic nematodes.   The identified presence of nematodes also aids this
identification step, but it is not essential.   These samples were plated on to
NBTA media (see Poinar & Thomas, 1984 Nematodes p238-280 in
"Laboratory guide to insect pathogens and parasites" Eds. Poiner & Thomas,
Pub. Plenum Press, New York).   Any colonies that developed that had
characteristic features (e.g. morphology, size, colour) of *Xenorhabdus* or
Photorhabdus strains were selected.   Non-luminescent colonies were
presumptively identified as *Xenorhabdus*.   The identity of those having
nematocidal activity as assessed in Example 3, is further confirmed using
16s rRNA sequence data (see Brunel et al 1997, Applied and Environmental
Microbiology 63,2: 574-580).

I73 and H31 strains were obtained in a similar way to strain C42 but they
were identified as belonging to the species *X. bovienii* when compared to the
X. bovienii type strain T228 using Restriction Analysis of the complete 16S

29

rRNA gene (see Brunel et al, 1997 Applied and Environmental Microbiology: 574-580), and partial 16s ribosomal RNA sequence analysis.

Example 2 - Cell growth and preservation

Subcultures of the *Xenorhabdus* species C42, I73 and H31 were used to inoculate three 9 cm diameter petri dishes containing L agar (10g tryptone, 5 g Yeast Extract, 5 g NaCl and 15 g agar per lt).   Plates were incubated for 48 hrs at 26°C and the resulting growth harvested by scraping off bacterial cells and thoroughly resuspending in 40 mls of 5% w/v lactose.   The cells were washed once by centrifugation (5000 x *g* for 10 mins), resuspended in 10 mls of 5% w/v lactose, dispensed into 1 ml aliquots and freeze dried (-60°C for 48 hrs) for medium term storage at 2°C.   Other stocks were re-suspended in nutrient broth containing 10% w/v glycerol (Protect) and frozen at -70°C.

Example 3- Activity of cells against *Caenorhabditis elegans*

The bioassays were performed by allowing *C. elegans* to feed on live bacterial cell suspensions spread over the surface of Luria broth agar (Luria broth containing 1.2%w/v agar) in segmented square petri dishes (2.0 x 2.0 cm per test well).   A minimum of three test wells, each containing 50-100 nematodes were used for each test.   Mortalities were recorded after 3 days at 18°C.

C. elegans was cultured on *Escherichia coli* at 18°C on 9 cm diameter LB agar plates.   Once the nematodes had colonised the complete plate they were re-subbed on a fresh plate to maintain stocks and the remainder re-suspended in 40 ml LB.   The tube was allowed to stand for 15 min and the nematodes settled to the bottom.   The concentrated nematodes were removed using a

sterile pipette and placed in 40 mls of fresh LB.   The process was repeated 5

more times to wash the nematodes away from the *E. coli* cells.   The

nematodes were then diluted so that approximately 50 nematodes were

present in 50 µl of LB.

The *Xenorhabdus* cells used were cultured in LB at 30°C/100 rpm for 24

hours and 50 µl spread on to the surface of each test well.   The control *E.*

coli cells were treated in a similar way but incubated at 37°C for growth.

After application the wells were air dried for 30 min, and 50 µl of the

nematode suspension placed in each well.   Again the wells were air dried for

30 min.   Plates were incubated at 18°C with 80% relative humidity for 3

days.

Xenorhabdus spp. C42, H31 and I73 gave 95% mortality, as compared with

no significant effect for certain other *Xenorhabdus* bacterial strains and *E.*

coli.   Thus these results clearly show that cells from *Xenorhabdus* C42, H31

and I73 are an effective nematocide.

Example 4 - Cloning of nematode active gene from I73

Total DNA was isolated from I73 using a Quiagen genomic DNA purification

kit (cat no. 10243).   To isolate DNA, cells were grown in Luria broth (10g

tryptone, 5g yeast and 5g NaCl per lt) at 26°C with shaking at 200 rpm to an

optical density of 1.5 A600.   Cells were harvested by centrifugation at 4000

x *g* and the DNA isolated using Quiagen 100/G tips, as per manufacturer's

instructions.   The purified DNA was stored at -20°C in TE buffer (10 mM

Tris, 1 mM EDTA, pH 8.0).

To obtain a representative I73 library, total DNA was partially digested with

*Sau*3A.   Approximately 25 µg of DNA was incubated at 37°C with 0.25 units

31

of enzyme.   At intervals of 5, 15, 30, 45 and 60 minutes, samples were removed and heated at 65°C for 10 minutes.   To determine the size of the resulting DNA fragments, the samples were separated on a 0.5% (w/v) agarose gel.   The samples containing a dominant DNA fragment size of between 30 and 50 Kb were combined and treated with shrimp alkaline phosphatase (Boehringer) for 20 minutes at 37°C.   The DNA was ligated into the *Bam*HI site of the Stratagene cosmid vector Supercos1 (scos) and packaged into the *Escherichia coli* strain XL Blue 1, using a Gigapack II packaging kit (Stratagene) following the manufacturer's instructions.

To identify individual cosmid clones with activity to *C. elegans*, single colonies were grown in individual wells of segmented square petri dishes on Luria agar, containing 50 µg/ml ampicillin at 30°C for 24 hours. To each well, approximately 50, mainly L4 and adult *C. elegans* larvae were added in 50 µl of Luria broth.   The dishes were incubated at 18°C and examined after 6 days for nematode development.

A total of 600 clones were examined and one coded cHRIM5 was found, which caused significant reduction in larval numbers, with no live L4 and adult larvae observed compared to on average, greater than 40 in all other clones tested.

Example 5 - Activity of cHRIM5, C42, H31 and I73 against *C. elegans*

Clone cHRIM5 was grown in 50 mls LB containing 50 µg of ampicillin per ml at 30°C/200 rpm for 40 hours. C42, H31 and I73 were grown in 50 mls LB at 26°C for 48 hours/200 rpm.   Cultures were centrifuged at 4000 x *g* for 10 minutes, washed once and resuspended in 5 mls of PBS (0.05 mM phosphate buffer, 0.125M NaCl).   To determine activity, 300 µl of cells were added in triplicate, to 1.2 ml of PBS containing 25, mainly L4 and adult *C.*

elegans larvae in multi well square dishes.   As a control, an equivalent amount of XL 1 Blue *E. coli* cells containing Supercos 1 were used to determine nematode survival.   The assays were incubated at 18 °C for 7 days before approximate nematode counts and observations were made.

Activity of cells on *C. elegans*

Cell line	No. and size of larvae/square	Cell turbidity
XL 1 Blue/Supercos 1	>100 (all stages)	Clear
XL 1 Blue/cHRIM5	<20(mainly small, L1,2 &3)	Cloudy
C42	<10	Cloudy
H31	<10	Cloudy
I73	<10	Cloudy

Thus cHRIM5, C42, H31 and I73 all gave a reduction in nematode numbers, and in particular cHRIM5 cells significantly reduced larval growth and development.   All four strains caused a reduction in feeding (as indicated by the cloudy cell suspensions).

Example 6 - DNA and protein sequences

Plasmid and cosmid DNA for cloning was prepared using the QIAGEN midi system (tip 100, cat. No 12143).   Cells were grown in Luria broth (Merck) at 37°C with shaking at 200 rpm for 18 hours.   Cells were harvested by centrifugation at 6,000 x *g* and the DNA isolated as per manufacturers instructions.   Restriction digestion (Roche, Life Technologies), dephosphorylation (Roche) and ligation (Life Technologies) were carried out using manufacturer's recommended conditions and as outlined by Sambrook et al.   Transformation was accomplished using electrocompetant cells and a

33

BIO-RAD Gene pulser set at 12.5V cm^{-2}.   Two µl of DNA was used to

electroporate 80 µl of early log phase *E. coli* DH5 alpha cells washed 3 times

in sterile water (centrifugation at 6000 x g for 5 mins) and resuspended in

1/100th the original volume in 10% (v/v) glycerol.   Luria agar containing

either kanamycin or ampicillin at 50 µg ml^{-1} were used to select clones where

appropriate.

DNA sequence analysis of cHRIM5 was completed by sequencing a number

of sub clones and primer walking, see figure 1 for the supercos vector, where

the numbers are kBp.   The sub clones used are as follows:

code	cHRIM5 treatment	vector used or remaining
A-380	*Hind*III digestion and self-ligation	deleted scos
B-387	*Bam*HI digestion and self-ligation	pUC 19-*Bam*H1 digestion
C-381	*Sal*I-*Bam*HI digestion	scos
E-391	*Sal*I-*Bam*HI digestion	pUC 19-*Sal*I *Bam*H1 digestion
F-392	*Sal*I-*Bam*HI digestion	pUC 19-*Sal*I *Bam*H1 digestion

Sub clone A-380 was constructed by digesting cHRIM5 DNA with the

restriction enzyme *Hind*III and re-ligating fragments, this clone contains a

deletion of the insert and scos cosmid DNA as the vector.   Sub clone B-387

is a *Bam*HI digestion of cHRIM5 cloned into the plasmid pUC19 also cut with

*Bam*HI and dephosphorylated.   Sub clone C-381 was obtained by digesting

CHRIM5 DNA with *Bam*HI and re-ligating the fragments, this clone contains

the scos cosmid as the vector.   Clones E-391 and F-392 were obtained by

cutting cHRIM5 DNA with *Sal*I and *Bam*HI and ligating these fragments into

the vector pUC19 also cut with these enzymes.

Sequencing was conducted using the artificial transposon AT2 (supplied by

Perkin-Elmer-Applied Biosystems, Primer Island Transposition kit, cat No.

34

403015) using the cosmid cHRIM5 and all sub-clones as target DNA.   One
µg of cHRIM5 DNA was incubated with the transposon AT2 for 1 hour at
30°C in a final volume of 20 µl.   After incubation the reaction was stopped
by adding 5 µl of 0.25M EDTA, 1% (w/v) SDS, and heat treatment at 65°C for
30 mins.   The DNA was desalted by dialysis against water.   One µl of the
reaction mix was used to electroporate 80 µl of early log phase *E. coli* DH5
alpha cells.   Colonies were selected on LB media containing 50 µg/ml
trimethoprim.   Once inserted the transposon mutants were used to provide
a range of positions of primer sites at random intervals throughout the
clones.   The two primers PI+ and PI- near the end of the transposon were
used to generate sequence data.   In addition standard primers for the
pUC19 and scos vectors were used to generate sequence data at the ends of
each clone.   DNA for sequencing was prepared using the QIAGEN ion
exchange media (qiawell8, cat. No. 17122).   Clones were grown in 1 ml of
Luria broth containing trimethoprin (50 µg ml⁻¹) for 18 hours.   Cells were
centrifuged at 13,000 x *g* for 5 mins and resuspended in 350 µl of buffer P1.
After 5 mins 350 µl of buffer P2 was added and the samples incubated for 5
mins at room temperature.   To this 350 µl of buffer P3 was added and the
samples left on ice for 15 mins.   After centrifugation at 13,000 x *g* for 15
mins the samples were loaded on the Qiagen column under vacuum, and
washed with buffer QC.   DNA was eluted with buffer QF (500 µl) at 50°C and
isopropanol precipitated (0.8 vol).   After centrifugation at 13,000 x *g* for 30
min, DNA was washed with 70% (v/v) ethanol and air dried for 10 mins.
The final pellet was resuspended in 10 µl of water.   Cycle sequencing
reactions using the Perkin-Elmer Applied Biosystems division Big Dye
reaction kit (cat No. 4303149) were prepared using standard conditions for
plasmid and cosmid sequencing.   Samples were analysed on ABI Automated
Sequencers.   DNA sequences were assembled using the DNA* software.
The complete sequence of cHRIM5 was obtained by primer walking to join
the final DNA contigs together.   The final sequence of cHRIM5ed2 is shown

35

in Figure 2. Analysis of the DNA using the software Clone indicated a number of ORF illustrated in Figure 3 and 4. Corresponding protein sequences are also presented at Annex I.

Example 7 - Fragments that encode nematocidal activity

To identify smaller fragments that encoded nematocidal activity, a series of sub-cloning experiments were performed using *E. coli* DH5 alpha. Qiagen midi and miniprep methods, restriction and ligations were used as for previous examples. Nematicidal activity of all constructs was determined as described in Example 4. In Figure 4, we show the deletions of cHRIM5 tested for nematicidal activity. Restriction sites and genes are indicated. Size in base pairs indicated on the map line. A cHRIM5, B cHRIM6, C cHRIM7, D cHRIM8, E cHRIM8, F cHRIM10, G *Nde*I deletion of cHRIM8, H Approximate positions (arrows) of three AT2 transposon insertions (tn58, tn26, tn43) in cHRIM9.

The cosmid cHRIM5 (figure 4A) was digested with the enzyme *Sal*I and religated. The resulting sub clone cHRIM6, illustrated in Figure 4B showed nematicidal activity. cHRIM6 was digested with the enzyme *Sma*I and religated, producing sub-clone cHRIM7 (Figure 4C). CHRIM7 was digested with *Bgl*II and the kanamycin resistance gene block (*nptII*, Pharmacia) cut with *Bam*HI was ligated into it. After selection on LB containing kanamycin (50µg ml⁻¹) and ampicillin (50µg ml⁻¹) the clone was digested with *Sal*I and religated, in effect creating a deletion from the *Sal*I site to the *Bgl*II site of cHRIM6 to generate CHRIM8 (figure 4D). By cutting cHRIM8 with *Nru*I a further deletion was made to create cHRIM10 (figure 4F). All the above clones maintained nematicidal activity.

Deletion of cHRIM8 with *Nde*I, removed a portion of the p14-2f gene (figure

36

4G), this reduced nematicidal activity. This indicates that the p14-2f gene or protein are important for nematocidal activity. Transposon mutagenesis of cHRIM9 (a clone very similar to cHRIM7 but deleted with *NarI* rather than *SmaI*) with the artificial transposon AT2 (Perkin Elmer Applied Biosystems) resulted in a number of inserts within this clone (figure 4H). Insert cHRIM9-tn43 was restriction mapped to an approximate position of bp 20,700 (on cHRIM5) within the p20-9r gene, this mutant retained nematicidal activity. This indicates that this gene is not essential for activity. Insert cHRIM9-tn58 mapped to an approximate position of bp 13,400 (on cHRIM5), within the p13-1f gene, nematicidal activity was reduced. This indicates that this gene, region of DNA or the blocking effect of the transposon in this position is important for activity. Insert cHRIM9-tn26 was restriction mapped to approximate position of bp 15,000 (on cHRIM5) within the p14-2f gene, nematocidal activity was reduced. This indicates that this gene, region of DNA or the blocking effect of the transposon in this position is important for activity.

Clone cHRIM6-tn43 was digested with *BglII* and *NotI* and cloned into the vector PLEX (Invitrogen cat. No. K450-01) cut with *BamHI* and *NotI*. The *E. coli* strain used was GI742 supplied by Invitrogen. The resulting plasmid insert (PLEX-*BglII*/tn43, Figure 5) places the p14-2f and p13-1f genes under the control of the bacteriophage Lambda P_L promoter. Figure 5 illustrates the cloning of DNA encoding nematocidal activity in the expression vector PLEX, where: A, plasmid clone; B, insert and gene locations; Tpr, trimethoprim resistance; Apr, ampicillin resistance; PL, bacteriophage lambda PL promoter; *, plasmid joins to form a circular molecule; **, incomplete genes. Selection of colonies on RMG media (described in the Invitrogen manual) containing ampicillin (50 µg ml^{-1}) and trimethoprim (50 µg ml^{-1}) prevents expression from the P_L promoter. Colonies were then cultured on LB containing Trimethoprim (50µg ml^{-1}) in 2.0 cm^2 wells for

nematocidal tests. The clone was active. This indicates that genes within this fragment have nematocidal activity. The clone PLEX-*Bg*II/tn43 was digested with *Cla*I and religated, this resulted in a deletion of part of the p13-1f gene, this clone had reduced nematocidal activity indicating the importance of this gene.

All these results indicate that the genes and gene products of p13-1f and p14-2f are important for nematocidal activity. Other smaller genes within the *Bg*II to *Nru*I sites of cHRIM10 and PLEX-*Bg*II/tn43 may also be essential. In addition genes outside this region within the remaining cosmid clone (cHRIM5) may also encode products with nematocidal activity, or may enhance the nematocidal activity of genes in the smaller region (*Bg*II-*Nru*I of cHRIM10 and PLEX-*Bg*II/tn43).

Example 8 - Field trials

Activity of strains selected in accordance with the above methods, or from depositary institutions which include bacteria which in nature are associated symbiotically with entomopathogenic nematodes, may be further assessed in field trials as follows.

Symbiotic bacteria in the absence of their nematode host can be inoculated into one or more portions of a field which is infested with nematodes, or into containers containing unsterilised soil from such a field. The bacteria can be inoculated onto the roots of plants, or into seeds. Periodically treated and untreated areas or containers can be assayed for nematode larva, egg, or cyst counts and for the presence of the inoculated bacteria by methods well known to those skilled in the art. A reduction in the number of nematode counts in areas in which the symbiote bacteria are present indicates control of the nematodes otherwise found in the untreated areas or samples.

Annex I - amino acid sequences

SEQ ID NO:1

PO-0f

ISWFATGIPTVDALLAEEFWHGDKQAFPPFTCRFTHFDPDKEQDVTLVPSTEEAYWLHRA

LQGQPLHSEVYGDDGTAQAGIPYTVMDSRPQVRLLTGLPGNSPTVWPSVIEQRTWQYERI

ADDPQCHQQVVLNSDRYGFPRETVDIAYPRRPKPAVSPYPDTLPATLFDSSYDEQQQQLR

LTRQRQHYHHLTDTEHQVLGLPDVMRSDAWGYPAARVPREGFTLEDLLAENSLIAPGTPL

TYLGHQRVAYTGTTGTEEKPTRQALVAYTETAVFDELALQAFNGTLSPEALEKKLIESGY

LSVPRPFNTGAESAVWVARQGYTDYGGSEAFYRPLAQRTTVQIGKNTLHWDTHYCAVVRM

QDAAGLYTDAAYDYRFLTPVQITDANDNQQHITLTALGQVSSGRFWGTEEGTPQGYTPPE

DRPFTPPSSVAEALDLKPDLPVANCMVYAPLSWMPLAHTYQEYIAGFTWQALLDAGVVTE

DKRVCALGFRRWVQRQGIVLNGQALADSREPVHVLTLATDRYDTDPDQQLRKSVTYSDGF

GRLLQSAVYHAPGEAWQRAADGSLITDAKGAPLVAHTATRWAVSGRTEYDGKGQPVRTYP

PFFLNAWQYLSDDSARQDLNADTHRYDPLGREYQVRTAKGYLRQNRLTPWFVVNEDENDT

LS

SEQ ID NO:2

P1-2r

YLPQRGQCDMLLVVIGIGYLNGGQEAVIIGGIRVQTRRILHTDDRTVMGIPMEGVFANLH

RRPLSQRTVKRLRPAVIGISLTGDPDRRFRTGIEWAWNRQITRLD

SEQ ID NO:3

P2-0f

SHLPARYGGRLTTLSRKGFMTVNRGDNLHQKTPEVTVLDNRGLTVRELRYHRHPNTPTTT

DERITRHRFTLSGQLAHSIDPRLFDLQQTDNTVNPNMIYDTALTGEVVRTRSVDAGNDLI

LNDITGRPVLAINATEVTRTWQYENDTLPGRPLSITEQPAGEAGRITERFVWAGNSQAEK

NSNLAGQCVRHYDTAGLNQTDSIALNGIPLSVTRQLLPDGTDADWQGNNEPAWNDRLAPE

NFTTLSTADATGAVLTTTDAAGNLQRVAYDVAGLLTGSWLRLAGGTEQVIVKSLTYSAAG

QKLREEHGNGVVTTYTYEPETQRLVGIKTKRPQGHAQGTKVLQDLRYEYDPVGNVVKVTN

DAEVTRFWRNQKVVPENTYVYDSLYQLVSATGREMANIVQQSTLLPTPSLIDSSTYSNYS

RTYNYDRGDNLTQIRHSAPATGNSYTTDITVSDHSNRAVLDTLTDDPAKVDALFTAGGHQ

IPLQPGQNLVWTPRGELLKVAPVVRDGQISDQESYRYDAASQRIIKTHVQQTANSSQAQS

TLYLPGLERHTTINGTTVKEVLHVITIGEAGRAQVRVLHWENGKPGAISNNQMRYSYDNL

IGSSGLEVDGDGQIISMEEYYPYGGTAVWTARSQTEADYKTVRYSGKERDATGLYYYGYR

YYQPWAGSWLSADPAGTIDGLNLYRMVRNNPATLDDKNGLAPGNRYVFFPFIHEDRIFRL

ASANVYRTEHNKSDIIAVVEDKALDSKLFTNSIEQFFKKPKGKAILKGSPDIKERLLNNI

VHDLSNMQVGDQLYVNAHGHSAKPFFYSDSGYSKIIMEQLQRGANYVAKDLVNKFKLPEN

ATIKISTCHSAEGKGAHITVTSTGTNEKMRYSSIIENKGEFSRSLAGTMENELIKLQPGR

VRGNVYGYLGATTFYGAKNEKVIHLKDGNLTTGVHEGKLSMFTKKNRFSENIFGLKVKRS
LTRTNFTGSGV

SEQ ID NO:4

p-2-9r

PAAEYVRDFTITCSVPPASRSQLPVSRPATSYATRCRLPAASVVVSTAPVASAVLRVVKF
SGASRSFQAGSLFPCQSASVPSGSSWRVTDSGMPLSAILSVWFSPAVS

SEQ ID NO:5

P3-2r

QRALLNDIGHFAPGGTDQLIQAVIDIGVLRHHFLVAPEAGNLRIVRHFHHVPHRVVLIAQ
VLQHLRPLCMSLWAFGFYANKALGLRLVGVGGHHAVAVLFAQFLTRGGIRQGFHDNLLCP
ARKPQPTASQQACYVIRHTLQVTGRIGGGQYRAGGIRRAQGGEVFRCQPVVPGGFIVSLP
VCVRTIRQQLARDGQRYAVKRNTVRLVQSGGVIVTHALSGQVAVLLRLTVPCPDKTLCDT
ACFASRLFCDTERASG

SEQ ID NO:6

P3-6r

SDRRQTGYAYSADHYRISGRSTVCTVRAGLMNYQCWLQHAATQLSESDSPKRDAEILLGY
VTGRSRTYLIAFDETLISSEELHQLDSLLVRRIQGEPVAYIIGEREFWSLPFAVSPATLI
PRPDTECLVEKALELLPDSPARILDLGTGTGAIALALASERNDCYVTGVDINSDAVMLAQ
HNAEKNAGKLAIHNVNFLQSEWFAAVGNQQFDMIVSNPPYIDERDPHLQEGDIRFEPATA
LIAAQNGMADLQAIVGQARHFLSPNGWLLLEHGWKQGTVVRNLFLEKGYQQIATFQDYGG
NERITIGRWNKNETHS

SEQ ID NO:7

P3-7f

ARRAVRRCGYCTGRTESRVPSVTTRCATAMITLSAAAVWRWTVTDKLSVWKNTTRTGALR
CGRRGVRQRLITRLCVTQARSGMQRGCIITATGITSRGRGAG

SEQ ID NO:8

P5-6r

WQNGGSSSTTPRYLAGCYVWYPCSARLSGNAKSLLAPDGEWMKHTLKSKASGNTFTGRLI
PTGRPTVVTIDKSGANTAALTLLNAEGEPQQGIEIRQNKYLNNRIEQDHRHVKRRIRPML
GFKSFRRAQT

SEQ ID NO:9

P5-7r

ALLFLSESRVMSLIRNAFKLLHYPVDIMAQCVRWSLTYALSLRNLEEMMAKRGIFVDHAT
IPRWVLRLVPLLSKAFRKRKKPVGSRWRMDETYIKVKGQWKYLYRSVDTDGQTDCGDYR

SEQ ID NO:10

P6-3f

VHSPSGAVAPGKFFIENFADTFPAPLPLHPFIDACIQQGFQLLPCLIAIAHSGKQAFECV
LLDRLALQGSQCLQALVLPVGDVNGQTAHGFLLIGYTQTHISTYNGLWLFITQGVRYRFV
RQTFVCRSLSFSEDDCTN

SEQ ID NO:11

P6-3r

RTCRERPRLMDYVLTKAAEADLRAIIRHTRKQWGDAQVRRYITALEQGIARLAVGQGSFK
DMSALFPALRMAHCERHYVFCLPRENAPALIVAIFHERMDLLTRLADRLK

SEQ ID NO:12

P6-6r

PQTIICANVGLCITDKEKTMSRLTIDITDRQHQSLKALAALQGKTIKQYALERLFPGMSD
SDQAWQELKALLDTRINEGMEGKGCGKSIGEILDEELAGSDRA

SEQ ID NO:13

P7-1f

NAHFLIVSKTNVVMSNQDPHNKRDSLFSAPIANLGDWSFDERVAEVFPDMVKRSIPGYSN
IISMIGMLASRFVTPGSQIYDLGCSLGAATLSIRRSINADNCRIIAIDNSPAMIERCRRH
IDSFKASTPVEVIEQNILDTDIQNASMVVLNFTLQFLHPDDRQKILKKIYAGLKPGGVLV
LSEKFNFEDQKIGELLFNMHHDFKRANGYSELEVSQKRSMLENVMRTDSVDTHKSRLKEV
GFQHVEVWFQCFNFGSLLAIKGTEQ

SEQ ID NO:14

P7-9f

TMIDFGNFYQLIAKHPLNHWLDSLPAQLSHWQKTSQHGQFSSWVKILENLPEIKPSHLDL
KNGVIAIHEPDLSKGEKARLHNILKILMPWRKGPFSLYDVEIDTEWRSDWKWERVLPHIS
PLEGKTVLDVGCGSGYHMWRMVGEGAQLVVGIDPTQLFLCQFEAIRKLLGNNQRAHLLPL
GIEQLPELQAFDTVFSMGVLYHRRSPLDHLWQLKNQLVSDGELVLESLVIEGDENQCLIP
GERYAQMRNVYFIPSAKMLKVWLEKCGFVDVRIVDHAATTPDEQRRTEWMKTESLVDFLD
PSDHSKTIEGYPAPLRAVLIARKP

SEQ ID NO:15

P8-4r

SLQIDREKVGLDRYPQPIERLRQPCATCDNHCHSRHQVRFFLLKEKYGAALAPISSQSAI
RYQFQRHTMKKGLFAMASIFSGYCGGELFHLLTDPAHESQ

SEQ ID NO:16

P9-8r

SSFRLNDDLLTNSYSEGFLMIKLEICCYSISCALVAQNAGADRIELSASPLEGGLTPSFG
ALQQSLQRLSIPVHPIVRPRGGDFCYNNMDFEAMKNDVARIRDMGFPGIVFGILSENGHI
DRLRMRQLMSLSGNMAVTFHRAFDMCFNPHVALEQLTELGVQRILTSGQQQNAELGLTLL
KELMQASRGPIIMPGAGVRVSNISKFLEAGMTEVHSSAGKIVPSTMKYRKVGVAMSSDDR
DVDEYSHYSVDGELVESMKGVMSLIKR

SEQ ID NO:17

P10-5r

YFGKNRRFVIYVTLMERNFYGLFNGEEMSHFSKISELQDLVADLAGFEQKLKQFEGHLGL
HFEQYSADHISLRCNESKIADRWRKGFLQCGQLISESIINGRPICLFDLNQPIVLLDWKI
DCVELPYPSQKHYVHQGWEHVELVLPVPPEQLICEAKKLLPQPLPDNFRMKESHPKGKNE
RLPNPILAV

SEQ ID NO:18

P10-7f

GNTVNIQVILSEKISNALIEAGAPTDSEAHVRQSAKAQFGDYQANGVMAAAKKVGIPPRQ
LAEKVVSQLDLQGIASKVEIAGPGFINIFLDKAWVAANIETTLKDEKLGITPVEPQTIVI
DYSAPNVAKQMHVGHLRSTIIGDAAARTLEFLGHKVIRANHVGDWGTQFGMLIAYLEKIQ
NENANDMALADLEAFYREAKKHYDEDEEFAIRARNYVVKLQGGDEYCRKMWRKLVDITMS
QNQETYNRLNVTLTEKDVMGESLYNDMLPGIVADLKQRGIAVKSDGATVVYLDEFKNKEG
EPMGVIIQKKDGGYLYTTTDIACAKYRHETLNASRVLYYIDSRQHQHLMQAWAIVRKTGY
IPESMSLEHHMFGMMLGKDGKPFKTRAGGTVRLSDLLDEAIERADTLIREKNPDMPEDEL
KKVVEAVGIGAVKYADLSKSRTTDYVFDWDNMLAFEGNTAPYMQYAYTRVSSIFKRADID
ENSLTLPVMLNEEREQALATRLLQFEETITTVAREGTPHVMCAYLYDLAGLFSGFYEHCP
ILNADSEELRQSRLKLALLTAKTLKQGLDTLGIQTVERM

SEQ ID NO:19

P11-1r

AQVSNMHLLGDIRCGIIDNDGLRFHWGDTELFIFQGSFYICCNPRFIKKNIDKTWACNFN
FAGNSLQIQLADDFFCQLSRRYSHLFSGSHHTIRLIVTKLCFGRLTDVSFTVGWSASFNQ
RIADFF

●

42

SEQ ID NO:20

P12-1r

HARVGVLHIRCRVAFKGQHIIPVENIVCSTALGKICIFHRANPYRFHDFFQFVFWHIWVF
LTNEGIRTLNRFIQQIGQSYCAAGTGFEWFTIFAQHHAKHVVFE

SEQ ID NO:21

P12-5r

YHASFQLCRRLLHTFYSLNTQSIKTLLQSFRCQQSQLQAALAQFFAIGIQDRAVLIETRE
QTGQIVQVCTHNMWRTFTGDGSDRFFKLQQAGCQCLLAFFIQHHRQCQAVFIDIRTFKDR

SEQ ID NO:22

P13-1f

FTLREDSMSDWTGVSTFNVILETGLDNCNIYANGLNMIGVIINITPTDDEGNFVDIDDVT
LNDNIKIVDYIDGSDIDGSDGWFYTGNPNEYNTIPNSQSYSLLKSENSQITQIKRYVSCS
NTSRLRTKSFSAKVTTTSGKVISITQNSINSSRVVINAIDATNFTDDELRTTKETRFENQ
SYTSHKSSTNSLYVHTWTIPRSLKLQNWRWEDYNNGWTWAQSCYYKTGADGGSESTRWLA
AGSIFPPGNYDGLWLDNDIALSGMAHKSYNVDTGINQLSFTRIIGKGFSWVYNISGLDRG
HAVIIIDQYGNKYRILFHAGYENSDPYLSSSIVY

SEQ ID NO:23

P14-2f

VYIKFLKLFRRITMSDNNEFFTQANNFTSAVSGGVDPRTGLYNIQITLGHIVGNGNLGPT
LPLTLSYSPLNKTDIGFGIGFNFGLSVYDRKNSLLSLSTGENYKVIETDKTVKLQQKKLD
NLRFEKDLKENCYRIIHKSGDIEVLTGFNNNAFDLKVPKKLLNPAGHAIYIDWNFEATQP
RLNRIYDDLDGHDIPLLNLEYQGLIKTILTLFPGQKEGYRTELRFLNRQLNSIHNFSLGN
ENPLTWSFGYTPIGKNGILGQWITSMTAPGGLKETVNYSNNNQGHHFPQSANLPVLPYVT
LMKQVPGAGQPAIQAEYSYTSHNYVGGGSNGIWNNKLDNLYGLMTEYNYGSTESRRYKDK
EGHDQIVRIERTYNNYHLLTSECKQQNGYIQTTETAYYAIIGHNFDSQPSQFQLPKTKTE
TWRSADNSYRSEITETTFDESGNPLTKVIKDKKTQKIISPSTHWEYYPPAGEVDNCPPEP
YGFTRFVKKIIQTPYDSEFKDDPEKFIQYRYSLIGSQSHVTLKIEERHYSATQLLNSTLF
QYNTDKSELGRLLKQTECTKGENGKTYSVVHKFTYTKQDDTLQQSHSITTHDNFTIHRSQ
VRSRYTGRLFSDTDTKDIVTQMSYDKLGRLLTRTLNSGTPYANTLTYDYELNNLQDDNRP
PFVITTTDVNGNQLRNEFDGAGRHVSQCLKDSDGDGKFYTIHTQQYDEQGRHHTSTYSDY
LTNGRQQTDPDKVHLSMSKSYDNWGQIANTHWSYGVSEKITVDPITLTATKQLQSNSNNV
QTGKEVTTYTPSQQPIQITLFDEAGHLQSCHTLTRDGWDRVRKETDAIGQCTIYQYDNYN
RVIQITLPDGTIVNRKYAPFSTDTLITDIRVNGISLGQQTFDGLSRLTQSQDGGRVWAYT
YSAGNDQCPSTVITPDGQFIHYQYQPELDDAVLQVASNEITQQFSYNPVTGALLKAVAEG
QSLTPIYYPSGRLKMENINDMKKMSYLWTLRGLENGYTDLTGTIQKISRDTHGRVTQIKD

SSIKTTLNYDDLNRHIGSQVTDLATGHMLTTTVEFDGLNREIGRKLCDSSGHTLDIQQSW
LKTQQLANRIVKLNGVLQRTEQYSYDSRNRLNQYKCDGAECPTDKYGHSIVTQNFTYDIY
GNITACHTTFADGTEDHATFKFANPTDPCQLTEVHHTHPDMPDNIRLKYDKAGRVINITD
NHGNTENFTYDTLGRLQNGQGSVYGYDPLNRLVSQKTDTLDCELYYRETMLVNEVRNGEM
IRLLRTGETIIAQQRASKVLLTGTDSQQSVILTSDKQNLSQEAYSAYGKHKSTANDASIL
GYNGERADPVSGVTHLGNGYRSYDPTLMRFHTPDSLSPFGAGGINPYSYCLGDPINRSDP
SGHLSWQAWTGIGMGIAGLLLTIATGGMAIAAAGGIAAAIASTSTTALAFGALSVTSDIT
SIVSGALEDASPKASSILGWVSMGMGAAGLAESAIKGGTKLATHLGAFAEDGENALLKST
SESSRIKWGVTRSLDREIVRNEEGQVIKDHSRGYTDNFMGKGEQAILVHGDKDGFLYHTE
GNKHNGKGPYTRHTPEQLVDYLKDNNIVDLTQGGDKPVHLLSCYGKSSGAADKMAKYINR
PVIAYSNKPTISQGLARIERKDFFLKSTYHSYDPRKIILGRTEKTVKPKTFRP

SEQ ID NO:24

P17-6r

LCYGHICLSGIPHRHIYIGSTYYGNRKSTVLYAAILHSVSLFYLLIAVFSASSAGYLTYG
LSYHTISVQFLGLSHQIPLLLSTYDQSLNLLLDYQYGDSGHRNLE

SEQ ID NO:25

P17-8r

SAQCIVGKVFRISMVISDIYYSTSLIIFQPDIIRHIWMSVVYLCQLAWVSWVGKFEGSMV
FCPICECGVTGGDIAIDIISKILCDYAMAIFVCRAFRTVTFILVQPITGIVRVLFCTLQY
SIQFHYSIC

SEQ ID NO:26

P18-7r

PSSLRTISLSKLLVTPHFILELSEVDLSKAFSPSSANAPRCVASLVPPLMADSANPAAPI
PIETHPSIEDAFGEASSSAPLTIDVISDVTLSAPNASAVVEVEAIAAAIPPAAAIAIPPV
AMVSSNPAIPMPIPVHACQLK

SEQ ID NO:27

P19-5f

AHCHIALFPCWHNPQYCQQHPDHHSNCHHQFKQEYPPSRQRRENITLTQLPIKHTGIEAG
SQTNRKRQTCMFQRANESKVHQLGQNQGRDRNFYWCFDILT

SEQ ID NO:28

P19-8f

PQSTPSSQNSRQLTPAESSQHQKQKSDHIEIMIPSEAPREYREQLHKATPARNRDVAPNP
SVFDILRDYHWKNFSPVKAAKSSLTPHPVHQKAIPLNDQRNTSMKQSLKPEMRQKLY

SEQ ID NO:29

P20-1r

GKNCINDQGNLPDRYTQNCRPHLTDNPPYGTVTERNPRQYQHADLFQMRKLIGQLQNPSG
NNGPTQRQHWRIAIRSHKQCKNDHTDIEQCRSKSRHRKAVPCIKNCASQRSQRNQKDIRK
RNSK

SEQ ID NO:30

P20-9r

NNTMNLLKSLAAVSSMTMFSRVLGFIRDAIIARIFGAGMATDAFFVAFKLPNLLRRIFAE
GAFSQAFVPILAEYKNQQGDEATRTFIAYISGMLTLILAIVSVIGVIAAPWIIYVTAPGF
TDTPDKFVLTRDLLRITFPYIFLISLASLAGAILNTWNRFSVPAFAPTLLNVSMIIFALF
VAPYCNPPVLALGWAVVAGGVLQLAYQLPHLKKIGMLVLPRISFRDSAVWRVIRQMGPAI
LGVSVGQISLIINTIFASFLVSGSVSWMYYADRLMELPSGVLGVALGTILLPSLAKSFSS
GNHEEYRKLMDWGLRLCFLLALPCAVALGILAEPLTVSLFQYGHFSAFDAEMTQRALIAY
CFGLMGLIVVKVLAPGFYSRQDIKTPVKIAIATLILTQLMNLAFVGPLKHAGLALSIGLA
ACFNASMLYWQLRKRDIFTPLAGWGIFLFKLVVAIAVMVGVLLAVLWVMPAWEQGNMAMR
LLRLMGVVIAGAGSYFAVLALMGFRLKDFAHRGLQ

SEQ ID NO:31

P21-7r

AIILIRDKLSRIFSRQISGEGMFGYRSASPKIRFITDRMVVRLVYERDAYRLAEYYSENK
DFLKPWEPTRDGSFYQPSGWTNRLNYIAELQRQNATFNFVLLDSDEREIMGVANFTNVVR
GAFHSCYLGYSLAEKLQGQGLMYEALQPAIRYMQRYQRMHRIMANYMPHNHRSGNLLKKL
GFEQEGYAKNYLMIDGVWQDHVLTALTDDAWGKVGL

SEQ ID NO:32

P21-8f

WCAMSLVSQARSLGKYFLLFDNLLVVLGFFVVFPLISIRFVEQLGWAALIVGFALGLRQL
VQQGLGIFGGAIADRFGAKPMIVTGMLLRALGFALMAMAHEPWILLLSCVLSGLGGTLFD
PPRAALVIKLTRPHERGRFYSILMMQDSAGAVVGALIGSWLLQYDFNIVCWIGASIFVLA
ALFNAWLLPAYRISTIRTPIKEGMMRVIRDRRFLYYVLTLTGYFVLSVQVMLMFPIIIHE
ITGTPTAVKWMYAIETAISLTLLYPIARWSEKHFRLEQRLMAGLFLMSICMFPIGWVNQL
HTLFGLLCLFYLGLVTADPARETLSASLSDPRARGSYMGFSRLGLALGGAIGYTGGGWLY
DTGRDLNMPQLPWILLGLSGLITIYALHRQFNQKKIDPVMLGRH

SEQ ID NO:33

P23-1f

KGANMKRFFLGAALVLVGLVSGCDQFKDFSINEGLMNDYLLKKVHYQKKISIPGIANANI
TLGDLSSQIGRQDPEKIELSTQAKVQLATLLGTIQADMKLTIKAKPVFDAEKGAIFVKGL
EIVDYQTTPEKAAAPVKALIPYLNTSLSEFFDTHPVYVLNPEKSKAEAAASQFAKRLEIK
PGKLVIGLTDK

SEQ ID NO:34

P24-4r

QVALQHGRRLGTITLFDNLLGLNQVMNEFSIVCRILGTLFNRAPQDPVLQPLITMIAEGK
LKQAWPLEQDEWLDRLQQNSELSVMAADYHALFTGESASVAVCRSDYTDGEESEVRQFLT
ERGMPLSDTPADQFGSLLLAVSWLEDQAAEDEIQAQITLFDEYLLPWCGQFLGKVEAHAT
SGFYRTLAIVTREALQALRDELESE

SEQ ID NO:35

P25-3r

DCMNIIFFHPSFNTDEWIQGIQARLPDAKVRQWVSGDQEPADYALVWQPPYEMLANRQGL
KGIFALGAGVDAIFKQESKNPGTLLADVPLIRLEDTGMGRQMQEYAITSVLHYFRRMDEY
KRYQEQRLWNPIAPHNRKEFVIGVLGAGILGRSVIGKLMEFDFNVRCWSRTSKQLDSVES
FYGKEQLGDFLSGCKVLINLLPDTPDTRGILNLSLFSQLKSGSYVINLARGAQLVEQDLL
VAIDKGYIAGATLDVFAEEPLSNMHPFWTHPRINVTPHIAANTIPEAAMDVICENIRRMV
QGEMPTGLVDRVRGY

SEQ ID NO:36

P26-0f

KTSQGFTSTTCSNGNVLKICGLITPCSSLIQRTYPNNMTIGIFSKESTAKNFGMGFLYYF
DLRVLSPFFKAPINIFTGWQHNTNFRKSRNSTIRLCSSTPNSKQYFTTSRKCHITGAGKY
RFSIENCFIKSG

SEQ ID NO:37

P27-0r

YSAGCSTVLKSSLNLQCDTFNCESFVMLTLNFSTSVNAKPSHIWAHYVDFDLRKKWEVDL
EYFQFEGEVKTGQYGRMILSGMPEIRFYLSNIEVNKEFTDQVNLPQMGILTFRHQIITDE
NNMACRVQVTVSFEPDANIPAVQAESFFKQGTQDLVESVLRLKSVVETVSPKPNLQLVYV
SDIESSTAFYKTIFNAEPIFASSRYVAFPAGGEVLFAIWSGGAKPDRAIPRFSEIGIMLP
SGKDVDRCFEEWRKNPEIKIVQEPHTEVFGRTFLAEDPDGHIIRVCPLD

SEQ ID NO:38

P27-8r

KGNQITMILYKGSKNYLFNQLNYDSCVLLEVDESVNLNGWDELSRAQRLLFLMEILRRYH

46

FPVQGKVLAQKLNISLRTLYRDIASLQAQGAIIEGEPGIGYVLRPGFVLPPLMFTQNEIE
ALALGANWVAKRADPQLKESANNAISKIAAVIPAELKQMLEASSLLIGPAATAVQPVVEI
QQIRQAINTRHKITLAYLDIKDIPSERTIWPFALGYFENISIVIGWCELREEFRHFRSDR
IMRLKIENQCYPRSRQVLLKEWRAMEKISR

SEQ ID NO:39

P27-9f

RKMTIYDLKPRFQNLLRPIVIYLYKQGITANQVTLTALFLSIFAGSLLSLFPSPHLYWLL
PVFLFIRMALNAIDGMLAREHNQKSHLGAIYNELGDVISDVALYLPFCLLPDVNSLSLLI
ILFLTILTEFIGVLAQTIGASRRYDGPIGKSDRAFIFGAYGLIIAIFPLALGWSISLFAF
MIILLLVTCYQRVVKALREIRLAEQSHSK

SEQ ID NO:40

P28-5f

GVNMTPQLDQRIAEEHYFTTSDNASLFYRYWPQQQANPDRAIIIFHRGHEHSGRIQHVVD
GLDLPDVPMFAWDARGHGKTEGPRGYSPSMGTSIRDVDEFVRFIATQYGIAMENIVVIGQ
SVGAVLVSAWVHDYAPKIRAMILAAPAFDIKLYIPFATQGLQLMQKARGIFFVNSYVKAR
YLTHDETRIASYNSDPLITREIAVNILLDLYQTAERVVKDAAAITLPTLLFISGSDYVVN
KKPQHQFYQQLNTPIKEKHVMDGFYHDTLGEKDRHLVFDKIRVFIERIFALPRYQHDYSQ
EDTWSHSADEFRTLSTSLPCLCPKKLSYQLMRKVMSTHWGRTSEGVCIGLKTGFDSGSTL
DYVYRNQPQGKGILGRILDKHYLNSIGWRGIRQRKIHIEMLIRHAIRSLREQNMPVHMVD
IAAGHGRYILDAINDFSKVDSILLRDYSEINVNQGQAYIEERDLTDKIRFIIGDAFNAES
ISSITPAPTLGIVSGLYELFPDNNLLRNSLRGFADVMTENGYLVYTGQPWHPQIEVIARV
LSSHRDSQPWIMRRRTQGEMDALVEAAGFEKLYQLTDNWGIFTVSIAKRVHR

SEQ ID NO:41

P28-5bf

HHNSINVLLKNIISPHQIMLLCFTVTGHNNRPIQTERSLFFTVVMSTQDVSSMSLTDSIC
LMFLCSRGMPVDTVRQKGRAVTAHPWERRFVMLMNLSDLLPLSTASPWKISWLSARVSER
Y

SEQ ID NO:42

P30-3f

INKYKMEHHMHSSLDSRRRLWLTGVIWLLFLAPFFFLTYGQVNQFTAQRSDVGTVMFGWE
HNIPFWSWSIIPYWSIDLFYGISLFICTHRREQWLHGWRLMTASLIACVGFLLFPLKFSF
SRPTTEGLFGWLFNQLELFDLPYNQAPSLHIILLWLLWLRYSAYVSGYWRGLLHIWSVLI
ALSVLTTWQHHFIDVLTGFAVGVILSYLLPVSYRWRWQPNQDRYARKLFGYYLTGSALFA
LIASLLGGSFWILLWPAVSLLMIALGYAGLGSSVFQKQPDGRMSLSARWLLAPYQLGAWL
SYLWFRRKSAPFNHITEGIILGSLPCQPVTAVSVLDITAEWHRRSDARTVNYVCQPQIDL

SUBSTITUTE SHEET (RULE 26)

LPLAPEALQSAVCTLDKLRQQGDVFVHCTLGLSRSAMVVAAWLLKQHPEYDINTVVAILR
KARPHVTFRQTHLDALSQWAKGYL

SEQ ID NO:43

P31-6f

QSCVKPDRMSRSDKHIWMPCLNGQKATYNGEHNMQPENLISKVIIATLKSWRFISTLSAF
SILIATAMLIAVFNTTALNNIALYAVLLFTTLYCQYYCWRTWLDCHYFQILNSSPEKSAE
FDQTLLLIFNKLPQSRTQNDRFNGAIKLLKKATIGLILQWILFFLFLLTLKYSA

SEQ ID NO:44

P32-3f

MNTRKINGIRPFSAFIDSCLKESYSFPRFIRDIIAGITVGVIAIPLAMALAIGSGVAPQY
GLYTAAIAGIVIAMTGGSRYSVSGPTAAFVVILYPVSQQFGLSGLLIATLMSGVILIVMG
LARFGRLIEYIPMSVTLGFTSGIAITIATMQVQNFFGLKLAHIPENYIDKVVALYQALPS
LQLSDTLIGLTTLLVLIFWPKLGVKLPGHLPALIAGTAVMGAMHLLNHDVATIGSSFSYT
LADGTQGQGIPPILPQFVLPWNLPDTHSLDISWNTVSALLPAAFSMAMLGAIESLLCAVI
LDGMTGKKHHSNGELLGQGLGNIAAPFFGGITATAAIARSAANVRAGATSPIAAVVHSLL
VLLTLLVLAPMLSYLPLAAMSAILLIVAWNMSEAHKVVDLIRHAPKDDIIVMLLCLSLTV
LFDMVRRDHYRHCAGITPVYAQNCQYDSNQHVIFNKRGERVIGRTN

SEQ ID NO:45

P33-4r

ESIGAKTSNVNNTSRECTTAAIGEVAPARTLAAERAIAAVAVMPPKKGAAILPNPWPSSS
PLEWCFFPVIPSRITAHSNDSIAPSMAIENAAGSNADTVFQLISRECVSGKFHGRTNWGR
MGGMP

SEQ ID NO:46

P33-5f

LSYSIWSVAITIGIVLASLLFMRKIANMTRISTSSLTSAEKGLLVVRINGPLFFAAAERI
FAELREKSADYQTIIMQWDAVPVLDAGGLHAFQGFVRELGKEKHIVVCDIPFQPLKTLAR
AKVMPIEGELSFYATLPKALKEMAVDYTPEVCASSEKIQGQ

SEQ ID NO:47

P34-3f

CMSDVENDRRTLGSLLHDTEAQHVNHQIVITKVAATVTQDHLVIAAFFEFFNNIAHLPRA
NKLWFFNINHSTGFRHRFNQIGLAGKEGWKLNHIHHIRDWLSLCRLMHVSDNFHAEGLFQ
FLKDFHPLFQPWPTIRADRRTVSLIKRRFKNIRNAQFLCHGDIVLTNPHGQIP

SEQ ID NO:48

P35-0r

LSCIRFIFLLIQQIYLPLTREGISMQQKVVNIGDIKVANDLPFVLFGGMNVLESRDLAMR
ICEHYVTVTQKLGIPYVFKASFDKANRSSIRSYRGPGLEEGMKIFQELKQTFGVKIITDV
HEPAQAQPVADVVDVIQLPAFLARQTDLVEAMAKTGAVINVKKPQFVSPGQMGNIVEKFK
EGGNDQVILCDRGSNFGYDNLVVDMLGFGVMQQATQGAPVIFDVTHALQCRDPLGAASGG
RRAQVAELARAGMAVGIAGLFLEAHPDPENAKCDGPSALPLAKLESFLMQIKAIDDVVKN
FPELDTSK

SEQ ID NO:49

P35-8r

VDGIKMKPIVNYEFNNTPLIDGIILVSKIIRPDFPQTLVSEQLTALVEEARQRLSSITDS
KVKLDSLLTLFYREWKFGGANGVYCLSDTLWLDRLLHSRQGSPVSLGTVFTHIAQALGLS
VQPVIFPIQLILRIDLLDQPTWFINPLNGDTLNEHTLDVWLKGNIGPTVRLKKQDLQEAD
NVSLVRKITDTIKVSLMEEKKMELALKASEVVLTFDPDDPYEIRDRGLIYAQLDCNHIAV
SDLSYFVEHCPEDPISEMIKMQINTIEQRLIVLH

SEQ ID NO:50

P36-7r

SDRRQTGYAYSADHYRISGRSTVCTVRAGLMNYQCWLQHAATQLSESDSPKRDAEILLGY
VTGRSRTYLIAFDETLISSEELHQLDSLLVRRIQGEPVAYIIGEREFWSLPFAVSPATLI
PRPDTECLVEKALELLPDSPARILDLGTGTGAIALALASERNDCYVTGVDINSDAVMLAQ
HNAEKNAGKLAIHNVNFLQSEWFAAVGNQQFDMIVSNPPYIDERDPHLQEGDIRFEPATA
LIAAQNGMADLQAIVGQARHFLSPNGWLLLEHGWKQGTVVRNLFLEKGYQQIATFQDYGG
NERITIGRWNKNETHS

SEQ ID NO:51

P37-5r

VEMREMAQEELKEAKIRNEELEQQLQLLLLPKDPDDERNCFLEVRAGTGGDEAAIFAGDL
FRMYSRYAEARRWRVEIISANEGEHGGYKEVIAKVSGDQVYGHLKFESGGHRVQRVPETE
SQGRIHTSACTVAVMPEIPEAELPDISPGDLKIDTFRSSGAGGQHVNTTDSAIRITHLPT
GIVVECQDERSQHKNKAKAMSVLAARIRAAEMRKRQEVEASERRNLLGSGDRSDRNRTYN
FPQGRVTDHRINLTLYRLDEVIEGKLDMLIQPIIIEYQADQLSALSEQD

Claims:

1. The use of a bacterial strain to control a target nematode, characterised
    in that in nature the bacterial strain is associated symbiotically with an
    entomopathogenic nematode.

2. The use according to claim 1, wherein the bacterial strain from nature
    is directly employed to control the nematode target, or is employed to
    give a recombinant bacterium employed to control the nematode target,
    or the natural or recombinant strain is employed as a source of a
    nematode control agent to control the nematode target.

3. The use according to claim 1 or 2, wherein the target nematode is not
    the same as the nematode with which the bacterial strain is found
    symbiotically in nature.

4. The use according to claim 1, 2 or 3, for control of helminthiasis in a
    human or a domesticated animal or the control of plant pathogen
    nematodes.

5. The use according to any preceding claim wherein the nematode to be
    controlled comprises one or more of *Haemonchus, Trichostrongylus,*
    Ostertagia, Nematodirus, Cooperia, Ascaris, Bunostomum,
    Oesophagosromuni, Chaberria, Trichuris, Strongylus, Trichonema,
    Dictyocaulus, Capillaria, Heterkis, Toxocara, Ascaridia, Oxyuris,
    Ancylostoma, Uncinaria, Toxascaris, Parascaris, Aphelenochoides,
    Anguina, Bursaphalenchus, Criconemella, Melodigyne, Ditylenchus,
    Globodera, Heliocotylenchus, Heterodera, Pratylenchus, Radopholus,
    Rotelynchus, Tylenchus, Trichodorus, Xiphenema, and *Caenorhabditis.*

50

6.   A composition for the control of parasitic nematodes which comprises as an effective agent a species of bacterium which is a symbiont of an entomopathogenic nematode, or an engineered bacterium, or a nematode control agent derived from a natural or engineered bacterium.

7.   A composition according to claim 6, wherein the bacterial species is of the genera *Xenorhabdus* or *Photorhabdus*,

8.   A composition according to claim 7, wherein the bacterial species is of the genus *Xenorhabdus*

9.   A composition according to claim 8, wherein the bacterial species is of , the species *Xenorhabdus bovienii.*

10.   A composition according to claim 8, wherein the bacterial species is: *Xenorhabdus bovienii* strain H31 deposited with NCIMB under accession number NCIMB 40985; *Xenorhabdus bovienii* strain I73 deposited with NCIMB under accession number NCIMB 40986; and *Xenorhabdus* strain C42 deposited with NCIMB under accession number NCIMB 41004.

11.   A composition according to any of claim 6, wherein the nematode control agent which is derived from a symbiont of an entomopathogenic nematode or from an engineered bacterium has functional activity against a nematode, and is a peptide.

12.   A nucleic acid encoding a peptide of claim 11.

13.   A nucleic acid according to claim 12, which nucleic acid comprises a

natural nucleotide sequence or a degeneratively equivalent sequence, or a functional variant thereof.

14. A nucleic acid according to claim 13, which is a homologous variant encoding a peptide which is a nematode control agent, the nucleic acid having 70% or more DNA sequence identity and/or the peptide having 70% or more amino acid sequence identity.

15. A nucleic acid according to claim 13, which is all or part of cosmid cHRIM5, in particvular p 13-1f or p 14-2f, and variants thereof.

16. A nucleic acid according to claim 13, 14 or 15, wherein the variant has a sequence which is a derivative by way of addition, insertion, deletion or substitution of one or more nucleotides.

17. A nucleic acid according to any of claims 12 to 16, which is part of a longer sequence and the nematode control agent is expressed as a fusion protein.

18. A nucleic acid complementary to a nucleic acid according to any of claims 12 to 17.

19. A nucleic acid for use as a probe or primer having a nucleotide sequence of at least 15 nucleotides, which sequence is present in a nucleic acid according to any of claims 12 to 18.

20. A method for identifying or cloning a nucleic acid according to any of claim 12 for a nematode control agent, which method employs a nucleic acid probe according to claim 19.

21. A method according to claim 20, which comprises the steps of:

(a)   providing a preparation of nucleic acid from a bacterium,

(b)   providing a probe,

(c)   contacting nucleic acid in said preparation with said probe under conditions for hybridisation of probe to any said gene or homologue in said preparation, and,

(d)   identifying said gene or homologue if present by its hybridisation with said probe.

22. A method according to claim 20, which comprises the use of two primers to amplify a nucleic acid encoding a nematode control agent, at least one of the primers having a conserved nucleotide sequence of at least 15 nucleotides.

23. A method according to claim 20, which comprising the steps of:

(a)   providing a preparation of nucleic acid from a bacterium,

(b)   providing a pair of nucleic acid molecule primers, at least one of which is a primer,

(c)   contacting nucleic acid in said preparation with said primers under conditions for performance of PCR,

(d)   performing PCR and determining the presence of absence of an amplified PCR product.

24. A recombinant vector comprising a nucleic acid according to any of claims 12 to 17.

25. A host cell containing a vector according to claim 24 capable of replication.

26. A host cell according to claim 25 which is a plant cell.

27. A method for producing a transgenic plant which comprises the step of regenerating a plant from a plant cell according to claim 26.

28. A plant produced according to claim 27 which is a crop species which can be maize, cotton, soya, rice, *Brassica* species, tomato, potato, sugar beet, barley, soybean, peanut, onion, rye, wheat, corn, banana, raspberry, bean, or a decorative or other plant.

29. A method of producing a peptide nematode control agent comprising causing or allowing expression of a nucleic acid according to claim 12.

30. An antibody or fragment thereof, or a polypeptide comprising the antigen-binding domain of the antibody, capable of specifically binding a peptide of claim 11.

1/14

Fig. 1

Molecule: Sequence Data
Description: chrim5ed2.seq,   37544 bps DNA

```
   1   ggatcagctg gtttgccacc gggatcccca ccgttgatgc cctgttagcg gaggaattct
  61   ggcacggtga caaacaggct ttcccgccct ttacctgccg ttttacgcat tttgaccctg
 121   ataaagaaca ggatgttact ctcgttccct cgacggaaga ggcttattgg ctgcaccggg
 181   cgttgcaagg ccaaccgtta cacagtgagg tctatggcga cgatggcacc gcgcaggcgg
 241   gtatcccta taccgttatg gacagtcggc cccaggttcg gcttctgacg ggtttaccgg
 301   gtaactcacc gacagtctgg ccgagtgtga ttgaacagag aacctggcag tacgaacgga
 361   ttgccgatga tccgcaatgc catcagcagg tggtgctgaa cagtgaccgc tacggttttc
 421   cacgggagac cgtcgacatt gcttatccgc gccgccctaa gcctgcggtg tcaccttacc
 481   cggatacgct gccggcgacg ttattcgaca gcagctatga tgagcagcaa cagcaattgc
 541   ggcttacccg gcaacggcaa cattaccatc acctgactga cactgaacat caagtgctgg
 601   gactgcctga tgtcatgcga agcgatgcct ggggctatcc ggcagcgcgg gtaccccgtg
 661   aaggtttcac cctggaggac ttgctggcag agaacagtct gatagccccg ggcacgccat
 721   tgacctattt agggcatcaa cgcgtggctt ataccggaac gaccggaacc gaagaaaaac
 781   cgacccgaca ggcgctggtg gcttataccg aaaccgcggt ttttgatgaa ttggccttgc
 841   aggcctttaa tggcacattg agtcctgaag ccctggaaaa gaaattaatc gagtctggtt
 901   atttgtctgt tccacgccca ttcaataccg gtgcggaatc ggcggtctgg gtcgcccgtc
 961   agggatatac cgattacggc gggtctgagg cgtttttaccg tccgttggct cagcggacga
1021   cggtgcagat tggcaaaaac accctccatt gggataccca ttactgtgcg gtcgtccgta
1081   tgcaggatgc ggcgggtctg tacacggatg ccgcctatga ttaccgcttc ctgacccccg
1141   ttcagataac cgatgccaat gacaaccagc aacatatcac actgaccgcg ctggggcagg
1201   tatcatccgg ccggttctgg ggcactgagg aagggactcc gcagggttat accccgcctg
1261   aagaccgccc atttacgcca ccgtcctcag tggcggaagc cctcgacttg aaaccggatc
1321   ttccggttgc caactccatg gtttatgcgc cgctgagttg gatgccgttg gcgcacacct
1381   atcaggaata tatagccggc tttacgtggc aggcactgct tgacgcgggg gtagtgacgg
1441   aagataagcg ggtttgtgcg ctgggtttcc gtcgctgggt gcaacgtcag ggcattgtgc
1501   tgaatgggca ggcattggcc gattcacggg aacccgtcca tgtcctaacg ctggccactg
1561   accgttatga cacggatccc gatcagcaac tgcgcaagag cgtcacctac agcgacggct
1621   tcgggcgttt attgcaaagt gcagtctacc atgcgccagg agaagcctgg caacgcgcgg
1681   cagatggcag cctgatcacg gacgcgaaag gggcgcccct cgtagcccat acggcaaccc
1741   gctgggcggt ctcaggcagg acagagtatg acggtaaagg gcaacccgtc cgaacctacc
1801   cgccattctt cctgaatgcc tggcagtacc tcagtgatga cagtgcacgg caggatttaa
1861   atgccgatac acaccgttat gacccgctcg gccgggaata ccaggtgaga accgccaagg
1921   ggtatctgcg ccaaaatcgg ctgacccct ggtttgtggt gaatgaggat gaaaacgaca
1981   cgctctctta attaacacga taacgttaaa taatcacacc ttcctgccag gtacgggggga
2041   aggttaacta ctctatcaag gaaagggttt atgactgtaa acagaggcga taacctgcat
2101   caaaaaacgc cggaagtgac ggttctggat aaccgggggc tgaccgttcg cgagctccgt
2161   tatcaccgcc acccaaatac ccccaccacc accgatgaac ggatcacccg ccatcggttt
2221   actctctcag gtcagttggc gcacagcatt gacccgcgtc tgtttgactt acagcagacg
2281   gataatacag tcaatcctaa catgatttat gatactgcac tgacggtga ggttgtgcga
2341   acaaggagtg tcgatgcggg taatgatctg atattgaatg acattaccgg ccggcctgtg
2401   ctggccatca atgcaaccga agtcactcgt acgtggcaat atgagaatga cactttaccc
2461   ggacgcccgc tcagtatcac agaacagcct gctggcgaag caggccgtat cacagagcgt
2521   tttgtctggg cagggaacag tcaggcggag aagaacagca acctggccgg acagtgcgtg
2581   cgtcactatg acaccgccgg actgaaccag acggacagta ttgcgcttaa cggcataccg
2641   ctgtccgtca cgcgccagct gctgccggat ggtacggacg cagactggca gggaaacaat
2701   gaacccgcct ggaacgaccg gctggcaccg gaaaacttca ccaccctgag cacggcggat
2761   gccaccggcg cggtactgac caccaccgat gcggccggta acctgcagcg tgtggcgtat
2821   gacgtagcag gcctgctgac tggcagttgg ctgcggcttg cgggcgggac agagcaggtt
2881   atcgtgaaat ccctgacgta ttccgccgcg ggtcagaaac tgcgcgaaga gcacggcaac
2941   ggcgtggtga ccacctacac ctacgagccg gagacccagc gccttgttgg cataaaaacc
3001   aaacgcccac agggacatgc acagggacg aaggtgttgc aggacctgcg ctatgagtac
3061   gacccggtgg ggaacgtggt gaaagtgacg aacgatgcgg aggttacccg cttctggcgc
3121   aaccaaaaag tggtgccgga aacacctat gtctatgaca gcctgtatca gctggtcagt
3181   gccaccgggc gcgaaatggc caatatcgtt caacaaagca cgctgttacc cactccttcc
3241   ctcattgata gcagtaccta cagcaactat tcccgcacct acaattatga ccgtgggggac
3301   aatctgacgc agatacgtca cagtgctccg gccactggta cagttacac cacggacatc
3361   acggtctcag atcacagcaa ccgggcagtg ttggacacgc tgacggatga tccggcaaag
3421   gtggatgcac tttttcactgc gggcgggcac cagatcccac tgcaaccggg acagaacctc
3481   gtctggacgc cgcgcggtga gctgctgaaa gtggcacccg tggtacgtga cgggcagatt
3541   tccgaccagg aatcctatcg ttatgatgcc gccagctc gcatcatcaa aacccacgtt
3601   cagcagacgg ctaacgactc gcaggcgcag agcacgctgt acctgccagg gctgagcggg
3661   cacaccacaa taaatggcac gacggtgaaa gaggtgctac acgttatcac gataggcgag
3721   gcgggccgtg cgcaggtgcg ggtactgcac tgggagaacg gaaagccggg tgccatcagt
3781   aacaaccaga tgcgctacag ctatgataac cttatcggca gcagcggtct ggaggtggac
3841   ggtgacggac aaattatcag tatgaagaa tactacccgt acggggggcac tgcggtgtgg
3901   acggcgagga gtcagacaga ggctgattac aagactgtgc gttactcagg caaggagcgg
```

Fig. 2

SUBSTITUTE SHEET (RULE 26)

chrim5ed2.seq

```
3961    gatgcaacgg  ggctgtatta  ttacggctac  cggtattacc  agccgtgggc  ggggagctgg
4021    ctgagtgcgg  acccggcggg  cactatcgac  gggctgaacc  tgtaccgcat  ggtcaggaat
4081    aacccggcga  cactggatga  taaaaacgga  ctagcgcccg  gaaatagata  tgtattttt
4141    ccatttattc  atgaggacag  gattttttcgt  ctggcaagcg  cgaatgttta  cagaacggaa
4201    cataataaat  ctgacatcat  tgcggttgta  gaagataaag  cattagatag  taaactattc
4261    accaatagta  ttgagcagtt  tttcaaaaaa  cctaaaggaa  aagcaatcct  gaaaggatcc
4321    cctgatatta  aagaaaggct  actcaataat  atagtacatg  acctgagcaa  tatgcaggta
4381    ggagatcagc  tgtatgtaaa  cgctcatggt  cattctgcga  aaccattttt  ttactccgat
4441    tcgggatatt  caaaaatcat  catggaacag  ctccaaagag  gggctaacta  tgtagctaaa
4501    gatttagtaa  ataagtttaa  attaccagaa  aatgcaacaa  tcaagataag  tacgtgtcat
4561    agtgctgaag  gtaagggcgc  tcatattacc  gtcacatcca  ctggaacaaa  tgaaaaaatg
4621    agatacagtt  ccattataga  gaacaaaggg  gaattttccc  ggtctttagc  aggtaccatg
4681    gaaaatgagt  taattaaact  acagccgggc  agagttcgcg  ggaatgtata  tggttatctt
4741    ggcgcgacaa  cgttctatgg  tgctaaaaat  gaaaaagtca  tacacctcaa  agatgcgaat
4801    ctgacaactg  gcgttcatga  aggcaagtta  tcaatgttta  ctaaaaagaa  ccgattttca
4861    gaaaacattt  ttgggttaaa  ggtaaaaaga  agtctgacgc  gaacaaactt  taccggcagc
4921    ggcgtataaa  aacaaatttc  aaaccgcatt  taaatacgga  cagccagcgc  gtgctcaaaa
4981    cgacctgacc  tgtcacgtcg  ttgcttcccc  gttacaccgg  caggtcggac  gcctgctggt
5041    ctttttacccg  ttttcactgg  atattgaccg  gcataccatg  agcatcacga  ccaaatgtgg
5101    ttctgtcgca  ttaacggcga  gttaatcaga  gatcccgcga  gtggttgttt  tttatactgc
5161    caatcgataa  aattgttccg  ccgccgataa  acattcacct  tcctcttgcg  aatacgggtc
5221    tttccggagc  atggcgacga  gttctatccc  tgccagtcac  gtttgtgccc  ggcgaaacga
5281    tttaaaacct  aacattggtc  gtatccgacg  tttgacatgg  cgatggtctt  gctcaatgcg
5341    gttattcagg  tatttatttt  gccggatttc  aatcccctgc  tgaggctcac  cttccgcatt
5401    gaggagggtg  agcȳcggcgg  tattggcccc  acttttatcg  atagtcacca  cagtcggtct
5461    gcccgtcggt  atcaaccgac  cggtaaaggt  atttccactg  gcctttgact  ttaatgtatg
5521    tttcatccat  tcgccatcgg  gagccaacag  gcttttgcg  tttccggaaa  gccttgctga
5581    gcaggggtac  caaacgtaac  acccagcgag  gtatcgtggc  gtggtcgacg  aagatcccc
5641    gtttttgccat  catttcctcc  agattacgta  agctcagcgc  gtaggtcaga  gaccaacgga
5701    cacattgggc  catgatatcg  acaggataat  ggaggagttt  gaatgcgttt  cggatcaggg
5761    acatcactct  ggactcactc  aaaaacagga  gagcttacct  gatattacgc  taatgcgaca
5821    gaacctattt  tatcgattga  ctgcataaat  agtcatcatt  cccacctccg  tacaaacttt
5881    ctctgttaat  gcgacagaac  ccttttttcc  atattgccgt  gcattgcctg  tagttgcctt
5941    aaattccttt  aaatttccta  tagttgctta  aaatatccat  aatattgcct  gagccgattg
6001    gcgaagcgcg  tcatttgagc  cggtcggcga  ggcgcgtcag  caaatccatc  cgctcgtgaa
6061    aaatcgccac  aattaacgca  ggcgcatttt  cacgcggcag  acaaaacaca  tagtgacgtt
6121    cacaatgcgc  catgcgcaat  gccggaaaga  gcgcgctcat  gtccttaaaa  gagccttggc
6181    cgacagcaag  ccgcgcaatg  ccctgttcca  gcgcggtgat  gtagcggcgc  acctgcgcgt
6241    cacccattg  cttgcgcgta  tggcggatga  ttgcgcgtaa  atcggcctca  gccgccttcg
6301    tgagtacata  gtccatcagg  cgcggtcgct  cccggcaagt  tcttcatcga  gaatttcgcc
6361    gatacttttc  ccgcacccct  tcccctccat  cccttcattg  atgcgtgtat  ccagcaaggc
6421    tttcagctcc  tgccatgcct  gatcgctatc  gctcattccg  ggaaacaggc  gttcgagtgc
6481    gtattgcttg  atcgtcttgc  cttgcaaggc  agccaatgcc  ttcaggcttt  ggtgctgccg
6541    gtcggtgatg  tcaatggtca  gacggctcat  ggtttttctcc  ttatcggtta  tacacaaacc
6601    cacattagca  catataatgg  tttgtggcta  tttattacac  aggggggtcag  atatcgtttt
6661    gtccggcaaa  cattcgtttg  tcggtcattg  tcattttcag  aagacgactg  caccaattaa
6721    tagggattag  agcctggtgt  gcatatgact  ggcactgttg  caaagtttga·gtcactgatt
6781    atgctaagtt  aaatgtttcg  taacgggagc  tcaccgtatg  aatgtattca  aaggccgtca
6841    ttttacaggc  attatcattt  tgtgggcagt  tcgttggtac  tgcaaatacg  gcatcagcta
6901    tcgtgaactc  caggaaatgc  tcactgagcg  tggcgtcaat  gttgaccata  cgactcttta
6961    tggttctgtt  gcaataagta  aagcctcggt  aatatctcac  ttatttgttg  ataagagtgt
7021    cgtcaatgtc  gttgatcgga  aaagccttca  tgacacccat  gcataagaga  agcccatcat
7081    taccaagggc  ggtattcctg  ccgcctgagg  gtttctgctg  attatccctt  tctgccttt
7141    cccgcattct  gttagaatgc  ccacttctta  attgtttcca  aaactaatgt  tgttatgtca
7201    aatcaagatc  ctcataataa  acgggacagt  ctgttctctg  ccccaatcgc  caatttaggc
7261    gactggagtt  tcgacgaacg  tgttgccgaa  gtctttcctg  atatggtgaa  acgttccata
7321    cccggttatt  ccaatatcat  ctccatgata  ggtatgctgg  ccagtcgctt  cgtgacgcca
7381    ggtagccaaa  tttatgatct  cggttgctcc  cttggggcgg  caactctgtc  catccgccgc
7441    agtatcaatg  ctgataattg  ccggattatc  gctatcgata  attcaccagc  catgatcgaa
7501    cgctcgcgcc  gccatattca  ttctttcaag·gccagtacac  ccgttgaggt  gatcgaacag
7561    aatatccttg  ataccgacat  tcaaaatgcc  tcgatggtag  ttttgaattt  cacattacaa
7621    ttcctgcacc  ctgatgatcg  ccagaaaata  ttgaagaaaa  tttacgcagg  attaaaaccc
7681    ggaggggttt  tggttctgtc  tgaaaaattc  aattttgaag  accagaaaat  tggcgagtta
7741    ctattcaata  tgcaccatga  tttcaagcga  gccaatggtt  atagtgagct  ggaagtcagc
7801    caaaagcgca  gtatgctgga  aaatgtcatg  cggacagatt  ctgttgacac  ccataagtca
7861    cgccttaaag  aagtcggttt  ccagcatgta  gaagtctggt  tccagtgttt  caatttcggt
7921    tcattattgg  caataaaagg  aactgaacaa  tgatcgattt  cggtaatttt  tatcaattga
7981    tcgccaagca  cccactaaac  cattggctgg  atagcctgcc  agcacaattg  agccactggc
8041    aaaaaacatc  acagcacggt  cagttcagct  catggtaaa  aattctggaa  aatttgcctg
8101    agatcaagcc  aagccacctt  gacctgaaaa  atggtgtcat  tgcgattcat  gagccggatc
8161    tgtcaaaagg  tgaaaaagct  cgcctccaca  atatcctgaa  aatattgatg  ccatggcgaa
8221    aaggccctt  ttcattgtat  gacgttgaaa  ttgataccga  atggcgctct  gactggaaat
```

<p style="text-align: center;">Fig. 2(i)</p>

chrim5ed2.seq
```
 8281    gggagcgagt  gctgccccat  atttctcctt  tagaaggaaa  aaccgtactt  gatgtcggct
 8341    gtggcagtgg  ttatcacatg  tggcgcatgg  ttggcgaagg  cgctcaattg  gttgtgggta
 8401    tcgatccaac  ccaacttttt  ctctgtcaat  ttgaagcgat  cagaaagttg  ttggggaaca
 8461    atcaacgagc  ccaccttctg  ccattgggca  tcgaacaatt  acccgaactg  caagcctttg
 8521    atacggtatt  ttcaatggga  gtgctctacc  accgccgctc  acctcttgat  catctgtggc
 8581    aactgaaaaa  tcaactggtg  tctgatggtg  agttagtgct  ggaaagttta  gtgattgagg
 8641    gtgatgaaaa  tcagtgcctc  attccgggtg  aacgctatgc  acaaatgcgg  aatgtctact
 8701    ttattccctc  ggccaagatg  ctgaaagtct  ggctggaaaa  atgtggtttt  gtcgatgtca
 8761    gaattgtcga  tcatgcggct  acaacacctg  atgaacagcg  ccggacagaa  tggatgaaga
 8821    ccgaatcact  ggtagatttc  cttgacccat  cagatcacag  taaaacaatt  gaaggctacc
 8881    ctgccccatt  gcgtgctgtc  ctcattgccc  gcaaaccata  atattgaata  aatattaatg
 8941    agtgaactgt  ccaatatggc  aattcactca  ttaagttcta  agatttcgct  ttccttatga
 9001    cgcaagcgat  atcacatcta  ccgcttaatc  aggctcatca  ctcccttcat  cgactcaact
 9061    aactcaccat  caacactgta  gtgagaatat  tcatctacat  cacgatcgtc  cgaactcatc
 9121    gccacccccta  cctttcggta  cttcatggta  gaaggtacaa  ttttacccgc  cgagctatga
 9181    acttccgtca  ttccggcttc  cagaaactta  ctgatattac  tcaccctgac  acccgcgccg
 9241    ggcataatta  tcggcccacg  gctggcttgc  atcagctctt  ttaacagcgt  cagccccagt
 9301    tcagcattct  gctgttggcc  tgatgttaaa  atacgctgca  ctccaagctc  tgtcagttgt
 9361    tccaacgcaa  catgcggatt  aaaacacata  tcaaaagcgc  gatgaaaagt  aacagccata
 9421    tttcccgaca  gtgacatcaa  ctgccgcata  cggagtctgt  caatatggcc  gttttcgctc
 9481    aaaatgccaa  aaacaatgcc  ggggaacccc  atatcacgga  tacgagcaac  gtcattttc
 9541    atggcttcaa  aatccatgtt  gttataacag  aagtctcccc  ctcttggccg  cacaatggga
 9601    tgcacaggaa  tagataaccg  ctgtaacgac  tgttgtaatg  ccccaaaact  gggtgtcaat
 9661    ccgccttcca  acgggcttgc  gcttaattcg  attcggtcag  cgcccgcatt  ttgtgcaacc
 9721    agcgcacagc  ttatgctata  acagcaaatt  tccagcttta  tcattaaaaa  gccctccgaa
 9781    tacgaattcg  tcaacaagtc  atcatttaac  ctaaaactac  tttattagtg  aacttattaa
 9841    ctatgacaac  taacttatct  taatgacatg  ttggaaatca  caaggtcaga  attttttact
 9901    ggaacagcat  gataaaaacg  tcattttttgc  cggctatacc  tcacttttga  caatttctct
 9961    gatacaaaaa  ggatgatatt  tgatcgtgat  ttcaccatca  gtgacagcca  aaatcgggtt
10021    cggcaaccgt  tcattttttc  cttttggatg  actctccttc  atccgaaaat  tatctggtaa
10081    aggttgaggc  aataactttt  tagcttcaca  aataagttgc  tctggtggta  caggcagcac
10141    cagttcgaca  tgttcccaac  cttggtggac  atagtgtttt  tggctgggat  aaggcaattc
10201    cacgcaatca  attttccagt  caagtagtac  tattggctgg  ttcagatcaa  ataagcagat
10261    cggacggcca  ttaatgatac  tttcagatat  taactgacca  cattgcagaa  agcccttacg
10321    ccaacgatcg  gctattttac  tttcattaca  acgcagggaa  atatggtctg  ctgaatattg
10381    ttcgaagtgt  aagccaagat  gcccttcaaa  ttgcttaagt  ttttgctcaa  atccggctaa
10441    atcagccact  aaatcctgta  actcagaaat  ttttgaaaaa  tgagacattt  cttccccatt
10501    aaataaaccg  taaaaattgc  gttccattaa  tgtgacataa  atcacaaatc  gtctattttt
10561    gccgaaatat  cactcagtaa  gcgactaatt  gaagttggca  taacgacgaa  tcgcctgaaa
10621    gacaggctaa  aaacaaaaag  taacaccacc  agaggtggct  gatggtagca  tgcaggaccc
10681    cgaatatggt  ataaaccccg  ttattttctc  ataacccaca  cgcttaaaag  tattgcattt
10741    ccaaaatgca  taagctttcg  tgcgtaactt  aaggtaacac  ggtgaatata  caggttattc
10801    tttcagaaaa  aatcagcaat  gcgctgattg  aagctggcgc  tccaaccgac  agtgaagctc
10861    acgtccgtca  atctgccaaa  gcacaatttg  gtgactatca  agcgaatggt  gtgatggctg
10921    ccgctaaaaa  ggtgggaata  cctcctcgac  aattggcaga  aaaagtcgtc  agccaactgg
10981    atctgcaagg  aattgccagc  aaagttgaaa  ttgcaggccc  aggtttttatc  aatattttc
11041    ttgataaagc  gtgggttgca  gcaaatatag  aaactaccct  gaaagatgaa  aagctcggta
11101    tcacccccagt  ggaaccgaca  accatcgtta  tcgattattc  cgcaccgaat  gtcgccaagc
11161    agatgcatgt  tggacacctg  cgctcaacca  tcattggcga  tgctgcggcg  cgtacccttg
11221    agtttcttgg  gcataaagtt  attcgagcca  accacgttgg  tgattgggga  acccagttcg
11281    ggatgctgat  cgcctatctg  gaaaagatcc  agaacgaaaa  tgccaatgac  atggcattag
11341    cggatttaga  agctttctat  cgcgaagcaa  agaaacacta  cgatgaagat  gaagagtttg
11401    ctattcgcgc  tcgtaactac  gtcgtcaaac  tgcaaggcgg  tgatgaatat  tgccgtaaga
11461    tgtggcgtaa  gctggtagat  atcaccatgt  cccagaatca  ggaaacttat  aaccgcctga
11521    atgtcacatt  gacagaaaaa  gacgttatgg  gtgaaagcct  gtataacgat  atgctaccgg
11581    gtatcgttgc  agatttaaaa  caacgtggaa  ttgccgttaa  gagtgatggc  gcgacagtgg
11641    tttaccttga  tgaattcaag  aataaagaag  gcgaacccat  gggcgttatt  atccagaaaa
11701    aagatggtgg  ctatctttac  accacgacgg  atatcgcctg  cgccaaatac  cgtcatgaaa
11761    ccctaaatgc  cagccgtgtg  ctttactaca  tcgattcacg  ccagcaccag  cacctgatgc
11821    aagcttgggc  aattgtacgg  aaaacgggtt  atattccaga  atccatgtca  ctcgaacacc
11881    acatgtttgg  catgatgctg  ggcaaagatg  gtaaaccatt  caaaacccgt  gccggcggca
11941    cagtaagact  gtccgatttg  ctggatgaag  cgattgagcg  tgcggatacc  ctcattcgtg
12001    agaaaaccc  agatatgcca  gaagacgaac  tgaaaaaagt  cgtggaagcg  gtagggattg
12061    gcgcggtgaa  atatgcagat  ctttccaaga  gccgtactac  agactatgtt  ttcgactggg
12121    ataatatgct  ggcctttgaa  ggcaacacgg  cacctttatat  gcaatacgcc  tacacgcgcg
12181    tgtcatctat  ctttaaacgt  gcggatatcg  atgaaaacag  cctgacactg  ccggtgatgc
12241    tgaatgaaga  acgcgagcag  gcattggcaa  cccgcctgtt  gcagtttgaa  gaaacgatca
12301    ctaccgtcgc  ccgtgaaggt  acgccacatg  ttatgtgtgc  atacctgtac  gatctggccg
12361    gtctgttctc  tggtttctat  gagcactgcc  ctatcctgaa  tgccgatagc  gaagaactgc
12421    gccgagccg  cctgaagttg  gctctgctga  cagcgaaaac  tttgaagcaa  ggtcttgata
12481    ctctgggtat  tcagactgta  gaacgtatgt  aataatcttc  tacaaagctg  aaaactggcg
12541    tgatattatt  ttattacgcc  agtttttcc  tttcttctat  tctgtcaaaa  attaccaatc
```

Fig. 2(ii)

chrim5ed2.seq

```
12601    tgacatataa ttaatcttga gctaacattt tgatatttaa tcatagaaat atatgaacac
12661    agaagcagtt gttatgaaaa aattatttat ttctaactgc tagccctacc aatctccata
12721    aaaaaacctg atttttattc actattaata attaatgata atttctattt taattaacct
12781    tgttataaaa aatagtattt taaaaaaaca ttttacatta tataaaatat atcaatcgac
12841    tctttatttc tttatccatt tataaaatat attttttacc aaaataatat ttaaatcata
12901    tattatattt acatcacgtt agatcaaaat aacaattttt tagtcgttaa cccagattca
12961    gaacggcacg atgatatata agtcacatgg gttgtaaata aaggaaaaag ataaaaaaga
13021    ggagatataat cttcgcattt cttcaatgaa gatggatata gatactgtaa ggtagtaatt
13081    taaatgaaat ccattaacaa attaatattt aatttacatt aagagaggat tctatgagtg
13141    attggactgg tgtttcaaca tttaatgtta ttcttgaaac aggattagat aactgcaata
13201    tctacgctaa tgggcttaac atgattgggg taattattaa tatcacaccc actgatgatg
13261    aagggaactt cgtagatatt gacgatgtta cactaaatga taacatcaag attgttgatt
13321    atatcgatgg aagcgacatt gatggcagtg acggatggtt ttatacagga aatcctaatg
13381    aatacaacac tattccaaat agtcagtctt attctttatt aaagagtgaa aattctcaaa
13441    ttacgcaaat taaacgatat gtttcttgtt caaatacatc caggctaaga accaagtctt
13501    tttctgcgaa ggtaaccact accagtggaa aagttatttc aataactcaa aatagcatta
13561    attcatctcg ggtagtaatt aatgcaatag atgcaactaa ttttactgat gatgaacttc
13621    gaacaacaaa agaaacaagg tttgaaaatc aatcctatac gtcacataaa tcatctacaa
13681    actctttata tgtgcatacg tggacaatac caagaagctt aaaactacaa aattggcgtt
13741    gggaagatta caataatggc tggacttggg cacaaagttg ctactataaa acaggagccg
13801    atggaggatc agagtcaacc cgctggttgg ccgctggttc aatctttcca ccaggaaatt
13861    atgatggcct gtggctagat aatgatatcg cactaagtgg tatggcacac aaaagctaca
13921    atgttgatac tggtatcaat caattgagtt ttacccgtat tataggtaaa ggtttcagct
13981    gggtttataa tatatccgga cttgataagg ggcatgccgt tattattatc gaccagtatg
14041    gtaacaaata tagaatatta ttccatgccg ggtatgaaaa ctcagatcct tacttgtctt
14101    catcaatagt atattaaaaa tagtgttacc aatggtgtgg tagcatttcc ccaatacgaa
14161    acttgaccta gtggctgtaa ttataattta ttttcacagc cactttttaa gtatacataa
14221    aattccttaa gttattcagg agaatcacca tgagtgacaa taatgagttt tttactcaag
14281    ctaataattt caccagcgct gtcagtggtg gcgttgaccc tcgcacagga ttatacaata
14341    tacaaattac tttaggtcac attgttggta acggtaacct tggcacctact ctgcctctta
14401    ccttaagcta ttctcctctt aacaaaacag atattggatt tggcattggt tttaattttg
14461    gattatcagt ctacgacaga aaaaattctt tattgtctct ttctaccggt gaaaattata
14521    aagtcatcga aaccgataaa acagtaaaac ttcagcaaaa aaaactcgac aatttacgct
14581    ttgaaaaaga cctaaaagaa aattgttatc gtattataca taaatccggt gatattgaag
14641    tgttaactgg tttcaataac aatgcctttg acctgaaagt ccctaaaaaa ctattaaacc
14701    ctgctggaca tgctatctat attgattgga attttggagc aactcaacct aggctaaatc
14761    gtatttatga tgatctggat gggcatgaaa taccattatt aaacctagaa tatcaaggac
14821    taattaaaac gatattaacg ctttttccctg ggcaaaagga aggctaccgt accgagctac
14881    gctttctaaa cagacaattg aacagcatcc acaactttag cttgggtaat gaaaaccctc
14941    tcacttggtc cttcggttat acccctatag gaaaaaatgg tattttgggg caatggataa
15001    caagtatgac cgctcctgga ggattaaaag aaacggttaa ttatagtaat aataatcagg
15061    ggcatcattt cccccaatca gccaatctac cggtgttgcc ctatgtcaca ttaatgaagc
15121    aggttcctgg agcaggacaa cccgctatac aagcaagaata ttcgtatacc tctcataatt
15181    atgtcggtgg gggatctaat ggtatatgga ataataaatt agataatctg tatggattga
15241    tgacagaata taattatggc tctactgaat cccgcagata taaagataaa gaaggccatg
15301    atcaaatagt ccgtatagaa cgcacataca ataattacca tctgttaact tccgaatgta
15361    agcaacaaaa tggatatata cagacaagtg agacagcata ttatgctatt attggccata
15421    attttgattc tcagccctca caattccagt tgccaaaaac caaaacagaa acttggcgta
15481    gtgcagataa cagctatcga agtgaaatta ctgaaaccac atttgatgaa agcggaaacc
15541    ccctaaccaa agtaatcaaa gataagaaaa cacaaaaaat aatctccccc tcaacgcatt
15601    gggaatacta ccctccggct ggggaggtcg ataattgccc accagaaccg tatggattta
15661    ctcgtttcgt aaaaaaaatc atacaaactc cctatgactc cgaatttaaa gatgatccgg
15721    agaaatttat ccagtatcgt tatagcctca ttggcagtca gagtcatgtg actttaaaaa
15781    tagaagagcg ccactacagt gcaactcaac ttctgaatag tactctattt caatataata
15841    cggataaaag tgaacttggt cgtttattaa aacaaactga atgtaccaaa ggagaaaatg
15901    gaaaaactta ttctgtcgtg cataaattta cctatacaaa acaggacgac acgctgcaac
15961    agagccattc cataaccacc catgataatt tcacaactca ccgcagtcag gttcgttccc
16021    gttataccgg gcgtctgttt tctgacacag atactaaaga cattgtaact caaatgtcct
16081    atgacaaatt gggtcgatta ctcacacgca cccttaattc cggtacacca tatgccaaca
16141    ctctgacata tgattatgaa ctaaataatc ttcaggatga caatcgccct ccgtttgtta
16201    ttaccaccac ggatgtaaat ggcaatcagc ttcgcaatga attcgacggt gccggacggc
16261    atgtcagcca atgcctgaaa gactccgatg gtgatggaaa attctatacg atacatacgc
16321    aacaatatga tgaacaaggg cgtcatcata catctacata ctccgactat ctcacaaatg
16381    gaagacaaca gacggatcct gataaggtgc atctgtctat gtcaaaatcc tatgataatt
16441    gggggcaaat tgcgaacaca cactggagtt atggggtttc agaaaaaata actgtagatc
16501    cgataacatt gacggccacc aaacagttac aaagcaatag caataatgtg caaacgggta
16561    aagaggttac aacttatacg ccaagtcaac aacctataca gattacgtta tttgacgaag
16621    caggccattt acagagttgt cataccctga ctcgggatgg ctgggatagg gttcgcaaag
16681    aaaccgatgc aataggccaa tgcactattt accaatatga taactataac cgagtcattc
16741    aaataacgct tcctgatggc accatcgtaa atcgcaaata tgcacccttt agtactgata
16801    cgctgataac agatattcga gtgaatggaa tttccttggg acagcaaacg tttgacgggt
16861    tgagtcgatt aacacaaagt caagatgggg gacgagtatg ggcttatact tattccggcag
```

<p style="text-align:center">Fig. 2(iii)</p>

chrim5ed2.seq
```
16921   gtaatgacca atgcccatca acagtaataa caccagatgg tcagtttatc cattatcaat
16981   atcagccaga attagatgat gcagtattac aagtagcatc aaatgaaatt actcagcagt
17041   tcagctataa cccagtcact ggggcattat taaaggcggt ggcagaggga caaagcttga
17101   cccctatcta ttatccatcg ggaagactta agatggaaaa tatcaatgat atgaaaaaaa
17161   tgagttacct atggacactt aggggtctgg agaacggtta cactgatctg actggaacaa
17221   tacagaaaat ttcgcgtgat acccatggca gggtgacaca aattaaagat tcgtcaataa
17281   agactactct aaattacgat gacctgaatc gccatattgg tagtcaagta acagatttag
17341   cgactggtca tatgttgaca acaacagtgg aatttgatgg cttaaaccga gaaattggac
17401   ggaaattgtg tgatagctca ggccatacgt tagatatcca gcagagctgg ctgaaaacac
17461   agcaattagc aaatagaata gtgaaactga atggagtatt gcagcgtaca gaacagtact
17521   cttacgattc ccgtaatagg ttgaaccaat ataaatgtga cggtgcggaa tgcccgacag
17581   acaaatatgg ccatagcata gtcacacaaa attttactta tgatatctat ggcaatatca
17641   ccgcctgtca caccacattc gcagatggga cagaagacca tgctaccttc aaatttgcca
17701   acccaactga cccatgccaa ctgacagagg tacaccacac tcatccagat atgccggata
17761   atatcaggct gaaatatgat aaggctggta gagtaataaa tatcactgat aaccatggaa
17821   atacggaaaa cttttaccta c gatacattgg gcagattaca aaacggtcaa ggtagtgttt
17881   atggttatga tccattaaat cgcttagtga gtcagaaaac agataccta gattgtgagc
17941   tgtactatcg ggaaaccatg ttggtcaatg aagtacgcaa tggagaaatg atccgtttat
18001   tacggacggg tgaaacaata atcgcacagc aacgcgcatc aaaagtcttg ctaacaggaa
18061   cagatagcca acagagcgtg atattaacga gtgataaaca aaacttgtct caagaagcat
18121   atagtgcata tggaaagcat aaatctacag caaatgacgc ttctatcctg ggctataatg
18181   gtgaacgcgc tgacccagtt agtggagtaa cacatttagg taatggttac cgctcctatg
18241   atccaacatt aatgcgcttc catactccag atagcttaag ccctttggt gctggaggga
18301   ttaatcccta ttcctattgc ttaggagacc caattaatcg ctcagaccct tctggtcatt
18361   tgagttggca agcatggaca gggattggca tggggatcgc tggattactg ctgaccatag
18421   cgacaggtgg aatggcaatt gcagcagcgg gaggtattgc ggcggcaatt gcttccacct
18481   ccacaactgc actggcattt ggggcactga gtgttacatc ggatataacg tctattgtta
18541   gcggtgcact ggaagatgct tcaccgaagg catcttctat actcggatgg gtttcaatgg
18601   gaatgggtgc tgccgggtta gctgaatcgg ccattaaagg tggcaccaaa cttgcgacac
18661   atctaggagc attcgctgag gacgggggaa acgccttact taaatcgact tccgaaagtt
18721   ctagaataaa gtggggagtg acaagaagct tagatagaga aattgttcgc aatgaagaag
18781   gtcaggtgat aaaagatcat agccgaggtt ataccgataa ctttatgggg aaaggagagc
18841   aggctatatt agttcatgga gataaagatg gatttttgta tcatacagaa ggaaacaaac
18901   ataataggaaa agggccatac actcgacata ctcctgaaca actcgttgat tatttgaaag
18961   acaataacat cgttgatctt acacaaggag gagacaaacc tgttcattta ttatcctgct
19021   atggaaaaag cagcggtgca gcagataaaa tggcaaaata tatcaacagg ccagttatcg
19081   cttattctaa taaaccaaca atatcacaag gattagccag aatagaaaga aaggactttt
19141   tcttaaaaag tacttaccat tcgtatgatc cacggaagat catactggga agaacagaaa
19201   aaacagtgaa accaaaaact tttcgcccct aataaccttg caaaattcaa aggtactggc
19261   agaagtcata taaataactc tatgactggg taaatgaaat cagtattcaa acattaaaca
19321   ggatgaagt ggtcatctta tcaaccgcca aataaaaat tgggcggttg tattgaataa
19381   aattatttat taatcaggga atcactgcaa tccccgatga gcaaaatctt tcagtctaaa
19441   tcccatcaag gccagaactg caaaataact gcctgctccc gcaatcacta cgcccattaa
19501   gcgcagtagg cgcattgcca tattgccctg ttcccatgct ggcataaccc acaatactgc
19561   caacagcacc ccgaccatca cagcaattgc caccaccaat ttaaacagga atatccccca
19621   tcccgccaaa ggcgtgaaaa tatcacgctt acgcagttgc caataaagca tactggcatt
19681   gaagcaggca gccagaccaa tagaaagcgc cagacctgca tgtttcaacg ggccaacgaa
19741   agcaaggttc atcaatttgg tcagaatcaa ggtcgcgatc gcaattttta ctggtgtttt
19801   gatatcttga cgtgaataaa agcccggagc gagaacttta accacaatca accccatcaa
19861   gccaaaacag taggcaatta acgcccgctg agtcatctca gcatcaaaag cagaaaagtg
19921   accatattga aataatgata ccgtcagagg ctccgcgaga ataccgagag caactgcaca
19981   aggcaacgcc agcaagaaac agagacgtag cccccaatcc atcagttttc gatattcttc
20041   gtgattacca ctggaaaaac ttttcgccag tgaaggcagc aaaatcgtcc ctaacgccac
20101   acccagtaca ccagaaggca attccattaa acgatcagcg taatacatcc atgaaacaga
20161   gcctgaaacc agaaatgagg caaaaattgt attaatgatc aaggaaatct gcccgaccga
20221   tacacccaga attgcaggcc ccatttgacg gataaacccgc catacggcac tgtcacggaa
20281   agaaatccgc ggcaatacca gcatgccgat ctttttcaga tgaggaagct gataggccaa
20341   ttgcaaaacc cctccggcaa caacggccca acccagcgcc agcactggcg gattgcaata
20401   aggagccaca aacaatgcaa aaatgatcat actgacattg agcagtgtcg gagcaaaagc
20461   aggcaccgaa aagcggttcc atgtattaag aattgcgcca gccaaagaag ccagcgaaat
20521   caaaaagata taaggaaacg taattctaag taaatcacgg gttaagacaa acttatccgg
20581   tgtatccgta aatcccggca gtcacata gatgatccaa ggtgcagcaa ttacacctat
20641   cactgagacg atagccagaa tcaatgtcaa catacctgag atatatgcaa taaaggtacg
20701   tgttgcttca tcccccttgtt gattttttgta ttcggcaaga ataggaacaa aagcttgcga
20761   aaaagcgccc tctgcaaaga tacggcgtaa caggttaggt aatttaaagg caacaaaaaa
20821   ggcatccgtc gccattcctg caccaaatat acgagcaata atggcatcac gaataaagcc
20881   cagcacgcga gaaaacatcg tcattgaact gaccgctgcc agtgatttca ataagttcat
20941   ggtattgttc taaagttgta ttcttatgga attaagcata aaaatgtaaa gctatcccat
21001   caggcatcat aaaaatggca tataaagcaa tctggcggga tagcagccgg tgtttaaagt
21061   ctaacagaca aaaacccctgt ctacattttc tatattacgc cccattagcc ttacccgag
21121   attcataaac ccactttgcc ccatgcatcg tcagtcaatg ccgtcagcac atgatcttgc
21181   caaacaccat ctatcattaa ataattcttg gcataacctt cctgctcaaa tcccaacttt
```

<div style="text-align:center">

Fig. 2(iv)

</div>

7/14

chrim5ed2.seq
```
21241  ttgagcaggt  tcccactacg  atggttatgt  ggcatgtaat  tagccataat  ccggtgcatt
21301  ctctgatagc  gctgcatata  gcggatcgca  ggttgcagcg  cttcatacat  caatccttgc
21361  ccttgcaatt  tctcagctaa  agaataacca  agataacaag  agtggaacgc  gccgcgtaca
21421  acattagtaa  aattcgccac  acccataatt  tcacgctcat  cagagtccaa  taatacaaaa
21481  ttaaatgtcg  cattctgccg  ttgtaactca  gcgatatagt  tcaaccgatt  tgtccatcca
21541  gagggttgat  aaaaactgcc  gtcccttgtt  ggctcccatg  gcttcaggaa  atcttttattt
21601  tctgaataat  actcagccaa  tcgataagca  tcacgttcat  ataccagacg  aacaaccatc
21661  ctatccgtaa  taaatcgaat  tttgggcgat  gcagaacgat  aaccaaacat  gccttctcct
21721  gatatttgtc  ttgaaaaaat  tctggataat  ttatctctta  ttaaaattat  tgcctattac
21781  cctacgataa  aaaaatatca  tctataaccc  tctaccttaa  agatgagatt  agggtcagaa
21841  taataagaac  ttcatattta  attctctcat  attttagtgg  tgcgcaatgt  cgttggtttc
21901  acaagcacgt  agctgggta   aatacttcct  gctatttgat  aatttattag  ttgtttttagg
21961  ttttttttgtc  gtttttcccc  taatttcaat  tcgtttcgtc  gaacaacttg  gctgggcggc
22021  attgattgtt  ggtttcgctc  tggggcttcg  tcagcttgtt  cagcaaggct  tggggatctt
22081  cggtggcgcc  atcgcagacc  gatttggtgc  caagccgatg  attgttactg  gcatgttatt
22141  gcgagcactg  ggttttgctc  tgatggcaat  ggcacatgag  ccatggatat  tgctgctttc
22201  ctgcgttcta  tcaggattgg  gaggaacatt  gtttgatccc  cccagagcgg  ctttggtcat
22261  taagttaacc  cgtccccatg  agcgagggcg  tttttattca  atcctgatga  tgcaggacag
22321  cgcaggtgcc  gtggttggcg  cactcatcgg  aagctggttg  ctgcaatatg  atttcaatat
22381  cgtctgctgg  attggtgcat  ccattttttgt  gctggccgca  ttatttaacg  cctggctact
22441  gcctgcatac  cgtatttcaa  caatccgtac  tcctatcaaa  gaaggcatga  tgcgggttat
22501  tagagatcgt  cggttccttt  actatgtgct  gacattgacg  ggttattttg  tcctgtcagt
22561  acaagtgatg  ctgatgtttc  cgattattat  ccatgaaatt  accggcactc  ctactgccgt
22621  caaatggatg  tatgccattg  aaaccgctat  ctccctgaca  ttgctctatc  ccatcgcacg
22681  ctggagtgaa  aaacatttcc  gactggagca  gcgcttgatg  gcgggcttat  ttttgatgag
22741  catctgcatg  tttccgatcg  gctgggtcaa  tcaattacat  acactgtttg  gcctgctttg
22801  cctgttttat  ttaggtttgg  taacagccga  tcctgctcgt  gaaacgctga  gtgcttcact
22861  gtctgatcca  cgggcgcgtg  gcagttatat  gggatttagc  cgtctgggtt  tagctctagg
22921  tggtgcgata  ggttacaccg  gtggagggtg  gctctatgat  actggccgtg  acttgaatat
22981  gccgcaatta  ccctggattt  tgctaggatt  gtctggtttg  attaccattt  atgctcttca
23041  tcgccaattc  aatcagaaga  aaattgatcc  tgtgatgctt  ggtagacatt  aatcctatta
23101  gaaatagtgt  aaaatctgcc  cattgaaaat  aaaaaggagc  caatatgaaa  agattttttct
23161  taggggcagc  attagtgctg  gtaggattag  tcagcggctg  tgatcaattt  aaagacttca
23221  gcatcaacga  aggtctgatg  aatgattatt  tgctcaaaaa  agtgcattat  cagaaaaaaa
23281  tcagcattcc  aggtatcgcg  aatgccaata  tcacgctggg  ggatttatcc  agccagatag
23341  gccgccagga  tcctgaaaaa  attgaactat  ccacgcaagc  aaaagttcaa  cttgcaacac
23401  tactgggtac  gattcaggct  gatatgaaac  tcactatcaa  ggctaaaccc  gtatttgatg
23461  cagaaaaagg  cgctattttc  gtgaaaggc   tggaaatcgt  agactaccag  acaacaccgg
23521  aaaaagcagc  ggctccggtt  aaggcattga  ttccttatct  gaatacctct  ttgagtgagt
23581  ttttcgatac  tcatccggtt  tatgttctga  atccagaaaa  aagcaaggcc  gaggcagcag
23641  cctcacaatt  cgctaaaagg  ttggaaatta  aacccgggaa  gttagttatt  gggttgaccg
23701  ataaataatt  tttatcgtca  ttgaaataat  aaggtgcaaat  tattaatgga  taatttgccc
23761  ttttatttta  tcaattagtg  accgatacac  tcgcctgttc  atggccttcg  gctgaactat
23821  tatcgtgaca  ctgtcactca  gattctaatt  catcacgcaa  tgcctgcaac  gcttcacgag
23881  tgacaatcgc  cagcgttcga  taaaaaccac  tggttgcatg  ggcttcaact  ttaccgagga
23941  actgcccaca  ccaaggcaaa  agatactcat  caaacaacgt  aatttgtgct  tggatttcat
24001  cttcagctgc  ctgatcttcc  agccatgaca  cagccagcaa  tagagagccg  aactgatcag
24061  caggagtatc  agacagtggc  attccccgtt  ctgtcaaaaa  ctgacgtact  tcactttctt
24121  ctccgtccgt  ataatcagat  cgacaaacag  caacactcgc  cgattctcca  gtaaacagag
24181  cgtgataatc  ggctgccatc  actgacaatt  cactgttttg  ctgtaaacga  tccagccatt
24241  catcctgttc  caaaggccat  gcttgtttta  gtttcccctc  agcaatcatg  gtgattaaag
24301  gttgcaaaac  gggatcttgc  ggtgcgcggt  taaacaatgt  gcccaatatg  cggcagacaa
24361  tagaaaattc  gttcataact  tgattcaatc  ccaataaatt  atcaaatagc  gttattgtcc
24421  ctaatcgcct  gccatgctgt  aaagcaactt  gttaatagcc  acgtacccta  tcgacgaggc
24481  cagttggcat  ttcaccctgt  accatccgcc  ggatattttc  acagatgaca  tccatcgcag
24541  cctcaggaat  agtgttagca  gcaatatggg  gagtcacatt  aatacgaggg  tgagtccaga
24601  atgggtgcat  atttgacaat  ggttcttcgg  caaacacatc  aagggttgct  cctgcgatat
24661  aacctttatc  aatagcaacg  agcagatcct  gttcgacaag  ctgcgctcct  cgcgccagat
24721  taatcacata  tgaacccgat  tttagttggc  tgaataatga  cagattaagg  ataccacgag
24781  tgtcgggagt  atcagggaga  aggttaatca  gcaccttgca  gccagaaaga  aaatcacccca
24841  attgctcttt  accgtaaaaa  cтттcgacac  tatcgagttg  ttttgacgtc  ctgctccaac
24901  aacgcacatt  aaaatcaaat  tccattaatt  tcccaatcac  acttcgccct  aatattccgg
24961  cccctaaaac  gccgataaca  aattcttttc  ggttatgcgg  agcaataggg  ttccaaaggc
25021  gctgttcttg  gtatcgttta  tattcatcca  tcgcggcggaa  ataatgcagc  actgaggtaa
25081  tggcatattc  ctgcatctgc  cttcccattc  ctgtatcttc  gaggcggatc  aatggaacat
25141  cagccagtaa  cgtaccggga  tttttcgatt  cttgtttgaa  aatcgcatcg  acaccggcac
25201  ccagtgcgaa  tatgcctttt  agcccctgac  gattggctaa  catttcataa  ggtggctgcc
25261  aaactaatgc  atagtctgcg  ggctcttgat  caccactgac  ccattgcctc  actttggcat
25321  caggcagacg  tgcctgaatt  ccttgaatcc  actcatcggt  attaaaggaa  gggtgaaaaa
25381  aaataatgtt  catacaatct  tattccttat  tgtttttttg  atagggttaa  cctattgcta
25441  aaatggttgc  aagcctctgc  tggaaagcga  ggaatgaaaa  tattaataat  gttacccagt
25501  taacatattt  accactgcat  attacaaaaa  gcgcatcggc  tttagtaaat  gactatcgaa
```

Fig. 2(v)

8/14

chrim5ed2.seq

```
25561    tattcaaatt gttttttatt tgtgtaatca gtcaaaaagc ctgaaaaaat cgtcataagc
25621    ctgttgacgc ctgccctgct tttccctata gtagcgcccc gttgcagcga cgaactcaag
25681    tgatatcgct acaacaacaa aatacggtga ggtgtccgag aggctgaagg agcacgcctg
25741    gaaagtgtgt atacgtgaaa acgtatcgag ggttcgaacc cctctctcac cgccatattc
25801    taagaaagag cctgaacaca atactaaggc tttttgtgg ttactcttga tagagcattg
25861    aatctataat ttagtaaccc ttgcggaaaa tccctgacag gacgaccgca gaaacaaaac
25921    acggtgaggt gtccgagagg ctgaaggagc acgcctggaa agtgtgtata cgtgaaaacg
25981    tatcgagggt tcgaacccct ctctcaccgc catctttcaa gagaaagcct gaacttatgt
26041    tcaggctttt tcgcatttat actccccaaa gtataggtga aaaacctcgc aagggttcac
26101    ctcaacaacc tgctctaatg ggaatgtctt aaagatttgt ggcttaatta caccttgttc
26161    tagcctaatc caaaggacat acccgaataa tatgaccatc gggatcttca gcaaggaaag
26221    tacggccaaa aacttcggta tggggttcct gtactatttt gatctcaggg ttctttcgcc
26281    attcttcaaa gcaccgatca acatctttac cggatggcag cataatacca atttcagaaa
26341    atcgcggaat agcacgatca ggctttgctc ctccactcca aatagcaaac agtacttcac
26401    caccagcagg aaatgccaca taacgggagc tggcaaatat cggttcagca ttgaaaattg
26461    ttttataaaa agcggttgaa ctctcgatat cagagacgta aacaagctga agattgggtt
26521    tgggagatac tgtctcaacg acagatttca gccttaatac gctttcaacc agatcttgcg
26581    taccttgctt aaagaaactt tcggcctgaa cagcgggaat atttgatca ggttcaaatg
26641    aaacggtcac ctgaacacga cacgccatat tgttttcatc tgtaataatt tgatgtcgga
26701    atgttaatat tcccatttga ggaaggttaa cctgatcggt gaattctta ttcacttcga
26761    tatttgaaag ataaaaacga atttccggca ttccacttaa tatcattctg ccgtattgac
26821    ccgttttgac ctccccttca aattgaaaat attcaagatc gacttcccat ttttttccgca
26881    aatcaaaatc gacatagtgc gcccagatat gggatggttt agcgtttacc gatgtagaaa
26941    aattgagtgt taacatgaca aaactctcac agttaaatgt atcacattga agattaagcg
27001    agctttttaa tacagtagaa cagcccgcag agtatcaatg gtgagtgaca atttctgtca
27061    gtagtcttta tttggctaac gagaaatttt ttccattgct ctccattctt tgagcaaatac
27121    ttgccttgaa cggggtaac attggttttc aattttcaaa cgcatgattc tatctgatct
27181    gaaatgacga aattcctcgc gtaattcaca ccatccaatc acaatgctga tattttcaaa
27241    atagcctaag gcaaatggcc atattgttct ttctgatggg atgtctttta tatccaaata
27301    agcgagggtg attttatgcc gggtattgat cgcctgacgt atctgctgaa tctcgacaac
27361    aggctgaaca gctgtcgcag caggcccgat cagtaaggag cttgcctcca acatttgttt
27421    caattctgct gggatcacag ccgcaatttt gcttattgca ttatttgcag attcttttag
27481    ttggggtct gcacgtttag ccacccaatt cgcgcccaat gccaacgcct ctatttcatt
27541    ttgtgtaaac atgagcggtg gtaacacaaa tccaggcctc aaaacgtatc ctattcccgg
27601    ctcaccttcg ataatcgcgc cttgagcctg caacgatgca atatcccgat acagtgttct
27661    taagctgata ttcaatttct gcgccaacac ttttccctga accggaaagt gataacggcg
27721    caatatttcc atgagaaata acaaacgctg tgctctagac aattcgtccc atccattcaa
27781    gttaaccgac tcatcaacct ctaataacga gcaactatca taatttaatt gattaaaaag
27841    atagttttt gatcccttgt acaagatcat tgttatctga ttgccctttt agatttttta
27901    ttttattaat aatgctgata aattgacctc taaaggactt agagaaaaat gaccatatac
27961    gatttaaaac cccgtttcca aaacttactg cgtcctatcg taatttatct gtataaacaa
28021    gggatcaccg caaatcaggt cactttaacc gcgctgttcc tgtcaatctt tgccggttca
28081    ctattgagcc tatttccctc gccccacctc tattggttgc tgcctgtttt tcttttcatt
28141    cgcatggctc tgaatgccat tgatggcatg ctggcacggg aacataacca gaagtctcat
28201    ctgggcgcta tttataatga attgggggat gtcatttctg atgttgccct ctacctcccc
28261    ttctgccttt tacctgatgt gaacagcctc agcctgttga ttatttttatt cctcactatc
28321    ttgaccgaat tcatcggcgt actggcacaa acgattggtg ·catcacggcg ctatgacggc
28381    ccgataggaa aaagtgaccg tgcttttatc ttcggagctt atggattgat tattgcgatt
28441    ttcccctttgg ccttgggctg gagtatctct ttgtttgctt tcatgatcat tttactcttg
28501    gtgacttgct atcagcgcgt tgttaaagcc ttacgtgaaa tccggctggc tgaacagtca
28561    cactccaaat gaggcgttaa catgacacca caactcgatc aacgtattgc tgaagaacat
28621    tatttcacca catcagataa tgcttctctg ttttaccgtt actggccaca acaacaggcc
28681    aatccagaca gagcgatcat tattttttcac cgtggtcatg agcactcagg acgtatccag
28741    catgtcgttg acggactcga tctgcctgat gttcctatgt tcgcgtggga tgcccgtgga
28801    cacggtaaga cagaagggcc gcgcggttac agcccatcca tgggaacgtc gattcgtgat
28861    gttgatgaat ttgtcagatt tattgccact cagtacggca tcgccatgga aaatatcgtg
28921    gttatcggcc agagtgtcgg agcggtatta gtctctgctt gggtacacga ctatgcgcca
28981    aaaatccgcg ccatgatcct cgcagcaccc gcatttgata ttaaattgta tatccctttt
29041    gccacgcagg gactgcaatt gatgcaaaaa gcacgagta ttttcttcgt gaattcctat
29101    gtgaaagcca gatatctgac tcacgatgaa acccgaattg cctcttataa tagcgatccg
29161    ttgattaccc gggaaatcgc cgtcaatatt ctcttggatc tttaccaaac cgccgagcga
29221    gtagttaaag atgccgccgc cattacacta cctaccctgt tgtttatttc aggcagcgat
29281    tatgtagtga acaaaaaacc acagcatcag ttttatcagc agctaaatac ccctatcaaa
29341    gaaaaacatg tgatggatgg cttctaccac gatacgttgg gtgaaaaaga tcgccatctg
29401    gttttttgaca aaatccgggt ctttattgag cgcatttttg cacttccgcg ttatcagcac
29461    gattacagcc aagaagatac ctggagtcac tctgccgatg aatttcgaac attaagcaca
29521    tcattaccgt gtctgtgtcc taagaaacct agctatcaat tgatgcgtaa ggtaatgagt
29581    actcactgtg gcagaacttc cgagggtgtc tgcatcggtc tcaaaacggg gtttgattcc
29641    ggctccacat tagattatgt ctaccgcaac caaccgcagg gtaagggcat tttggggcga
29701    atactcgata agcattattt gaacagcatt ggttggcgcg gtatacgcca gcgcaagatc
29761    catattgaaa tgttgatccg ccatgctatt cgcagtctac gtgaacagaa tatgcctgtg
29821    catatggttg atatcgccgc cggacacgga cgctatattc ttgacgcaat caacgatttc
```

Fig. 2(vi)

chrim5ed2.seq

```
29881    agcaaagtcg attctatttt gttaagggac tatagcgaaa tcaatgttaa tcaagggcag
29941    gcttatattg aggagcgcga tctgacggac aaaattcgtt ttattatcgg tgatgccttt
30001    aatgctgaaa gcatctcatc cattacgcca gcgccgacac tgggtattgt atccggtctc
30061    tatgaattgt tccctgataa taatttactc agaaattcgc tacgcggctt tgctgatgtt
30121    atgacagaaa atggttatct ggtgtacacc ggccaaccgt ggcatccaca aattgaggtc
30181    atcgcccgtg ttctttccag ccatcgtgac agtcaaccgt ggatcatgcg cgccgtact
30241    caaggggaaa tggacgcatt agtggaagcc gccgggtttg aaaaactgta ccaactgaca
30301    gataactggg gcattttcac tgtttcgatt gccaacgtg ttcatcgctg atgaataaat
30361    aaatataaga tggaacacca catgcactgt tctctcgata gtcgtcggcg cctatggctg
30421    acaggtgtta tctggctatt gtttctggct ccgttttttct ttcttactta tggccaggtc
30481    aatcagttca cggcacaaag aagcgatgtc ggcactgtga tgttcggttg ggaacataac
30541    atccctttttt ggtcatggtc gattatccct tactggagta tcgatctgtt ctacggaata
30601    tcgttattta tctgtaccca tcgccgtgaa cagtggcttc acggctggcg attaatgacc
30661    gcatcactga ttgcctgtgt tggattctta ctgttccctc tgaaattttc gttctcccgc
30721    cccaccacag aaggcctatt tggctggtta tttaatcaac tggagttatt tgatctgccc
30781    tataatcaag ccccttccct gcacattatt ctgctgtggt tgctctggct gcgctattca
30841    gcctacgtga gtggttactg gcgtgggttg ctgcacattt ggtcagtgct gattgcactc
30901    tcggttctga cgacttggca gcaccatttt atcgatgtac taacgggttt tgccgttggt
30961    gtcatcctca gttacctact gccggtttca taccgctggc gctggcaacc taatcaagat
31021    cgctatgcac ggaagttatt cggctattat ctgacaggca gcgctttgtt cgcgcttata
31081    gcgagtctgc tgggggggag tttctggata ctgctgtggc ctgctgtatc gttactgatg
31141    atcgcactgg gctacgcagg attaggcagc tccgtgtttc aaaaacagcc agatggccgg
31201    atgtcactgt ctgcacgctg gctactggcg ccataccaac tgggagcatg gctctcttat
31261    ctctggttcc ggcgtaaaag cgcacctttc aaccatataa ctgaagggat tattctcggc
31321    agcctgcctt gccagcccgt tacggcggtc agtgtccttg atataaccgc tgagtggcac
31381    aggcgatcgg atgcccgcac agtaaattat gtttgccagc cgcaaatcga cttactgccg
31441    ctggcacctg aagctctaca atcggcagtt tgtacgctgg ataaactacg ccagcaggga
31501    gatgttttcg ttcattgtac gcttggactg tcacgcagtg cgatggtggt agcagcatgg
31561    ctactgaaac agcatcctga atatgatatc aacactgtcg tagcaatcct gcgtaaagcc
31621    agaccgcatg tcacgttcag acaaacacat ctggatgccc tgtctcaatg ggcaaaaggc
31681    tacctataac ggggaacata acatgcagcc ggaaaatctg atcagcaaag tgattatcgc
31741    aacgttaaaa agctggcgct ttatatccac actatctgct ttttctatcc tgatcgcgac
31801    tgcaatgctg attgctgtct tcaacactac cgccttaaac aacattgcac tctatgccgt
31861    actattattc acaacgctgt actgccaata ctattgttgg cgcacttggc ttgactgcca
31921    ctattttcag atcctcaatt catcccctga aaaaagcgcc gagttcgatc aaacgttatt
31981    gctgatattt aacaagttac cccaatcacg gacacagaat gatcgcttta acggagcaat
32041    caaaactgtta aaaaaggcta cgattggtct gatcctgcaa tggatactgt ttttcctgtt
32101    tctgcttact ttgaaatatt cagcctgaat tcagctttaa tctgacaaag tcagaacgta
32161    acgatgctac attttctcga ctgtactact attaactaac ttttagacct gtaacacctt
32221    tattgggtga taaaagagat actcttacat attcttttttc agcccgtcat gcggacgcct
32281    tatttttttgg ttttagatta aatgaatact cgtaaaatta atgggatacg cccatttagt
32341    gcgtttattg actcatgtct gaaggaatct tactctttcc cccgttttat cagagatatc
32401    atcgctggga ttaccgtggg tgttatcgct atcccattgg caatggctct ggcgatagga
32461    agcggagttg caccacagta tggcctgtat actgcccgta tcgccggcat tgtcatcgcc
32521    atgaccggag gctcacgtta tagcgtttcc ggcccaacgg cggctttttgt ggtgatcctt
32581    tatcctgttt cacagcagtt tggtttgagc ggcctgctca ttgcgacgct gatgtcaggt
32641    gtgattttga ttgtgatggg attggcacgt tttggccggc ttatcgaata tattcctatg
32701    tctgttaccc ttggatttac ttccggtatt gccatcacta tcgctaccat gcaggtgcaa
32761    aatttctttg gcctgaaact ggcacatata ccggaaaatt atattgataa ggtagttgca
32821    ctttatcaag ccctgccttc attacaattg agtgatacgc ttatcgggct gactacgctt
32881    ctggtactga ttttctggcc gaaactggga gtaaagttac cgggtcactt acccgctttg
32941    atcgcgggta cagctgttat gggcgcaatg catctgctga accatgatgt cgccaccatt
33001    ggttcatcgt ttagttacac actggcggat ggtacgcagg gtcaaggcat tcccccatt
33061    cttccccaat ttgtcctgcc gtggaatttg cccgatacac attctctcga tattagctgg
33121    aataccgtat cggcattgct gcccgctgcg ttttcgatgg ccatgctggg tgcgattgaa
33181    tcgttactgt gtgcagtgat tctggatggt atgacaggga aaaaacacca ttctaacggt
33241    gagctgcttg gccaggggtt gggcaatatt gccgcccctt tctttggtgg cattaccgcc
33301    actgcggcta tcgcccgttc agccgccaat gtgcgggcag gtgcaacttc cccgatagcc
33361    gctgtggtgc attccctgct ggtattatta acattgctgg ttttggctcc gatgctctct
33421    tatttaccac tggcggcaat gtcagccatt ctgctgattg tcgcgtggaa tatgagcgag
33481    gcacataagg tagtggattt aatacgccat gcgcctaaag atgacattat tgtcatgctt
33541    ttgtgtctgt cattgactgt cctattcgat atggtccgtc gcgatcacta tcggcattgt
33601    gctggcatca ctcctgttta tgcgcaaaat tgccaatatg actccgaatca gcacgtcatc
33661    tttaacaagc gcggagaaag ggttattggt cgtacgaatt aacggcccctt tattcttcgc
33721    tgccgccgaa cgtattttttg ccgaactgag agaaaaaagt gctgattatc aaaccatcat
33781    catgcagtgg gatgccgtac ccgttttgga cgctggcgga ttacgctt ttcagggttt
33841    tgtgcgcgaa cttggcaaag aaaaacatat cgtcgtatgt gatattccct tccagccatt
33901    gaaaacgctg gcaagagcca aagttatgcc gattgaagga gagctgagtt tttatgctac
33961    cttacccaag gcactaaaag agatggcagt tgattacacg cctgaggtgt gtgcttcttc
34021    agaaaagatt caagtcagt aacaacaagt caccctctgc cagttatgct ggcagagggt
34081    gactaataga agactagcgt aggaatttat ttgtggtat ccagttccgg gaaatttttc
34141    accacgtcat caatcgcttt aatttgcatc aggaatgact ccagttttgc caatggcaaa
```

Fig. 2(vii)

SUBSTITUTE SHEET (RULE 26)

chrim5ed2.seq

```
34201  gcagacgggc catcacattt ggcattttct ggatctgggt gcgcttcaag gaacagacct
34261  gcgatcccca cagccatacc cgcacgagcc agttcagcaa cctgcgcgcg acggccaccg
34321  gaagctgcac ctaatgggtc gcggcactgt aatgcatgag tgacgtcgaa aatgaccggc
34381  gcaccttggg tagcttgttg catgacaccg aagcccagca tgtcaaccac cagattgtca
34441  taaccaaagt tgctgccacg gtcacacagg atcacctggt cattgccgcc ttctttgaat
34501  ttttcaacaa tattgcccat ttgcccaggg ctaacaaact gtggtttttt aacattaatc
34561  acagcaccgg ttttcgccat cgcttcaacc agatcggtct ggcgggcaag gaaggctgga
34621  agctgaatca catccaccac atccgcgact ggttgagcct gtgcaggctc atgcacgtca
34681  gtgataattt tcacgccgaa ggtttgtttc agttcctgaa agattttcat cccctcttcc
34741  agccctggcc cacgataaga gcggatagaa gaacggttag ccttatcaaa agacgcttta
34801  aaaacataag gaatgcccag tttttgtgtc acggtgacat agtgctcaca aatccgcatg
34861  gccaaatccc gtgattcaag gacgttcatt ccaccaaaca atacaaatgg cagatcattt
34921  gcgaccttga tatcaccaat attaaccact ttctgttgca tgcttatacc ttctcttgtt
34981  aagggcaaat aaatttgctg tatcaataaa aaaataaacc taatgcagga caatcaaccg
35041  ctgttctatg gtgttaattt gcattttttat catttctgag attgggtcct cagggcaatg
35101  ttcgacaaaa taactcaaat ccgaaacagc aatatgattg cagtcgagct gggcatagat
35161  aagcccccga tcgcggattt cataggggatc atcgggatca aacgtcagca ccacttcgct
35221  ggccttaagc gccagttcca tcttttttctc ttccatcaga gaaactttga tggtgtcagt
35281  gattttgcgc acgaggctga cattatcggc ttcctgcaaa tcctgttttt tcagacgaac
35341  agttgggcca atattacctt ttaaccagac atccagcgta tgttcattca gcgtatcccc
35401  attcaaggga ttaatgaacc aagtgggctg atcaagcaaa tcaatccgca atatcagttg
35461  gattggaaat atgacaggct gtaccgacag ccccagcgcc tgagcaatat gcgtaaacac
35521  cgtacccaat gatacaggtg agccttgacg tgaatggagt aagcgatcca gccacagggt
35581  atctgataga caatacaccc cattagctcc accaaacttc cattcccgat aaaaaagtgt
35641  tagcagcgaa tccaatttca ctttggaatc ggtaatggag gaaagcctct gccgggcttc
35701  ttcaaccaat gcagttagct gctcactcac cagagtctga ggaaaatcag ggcggataat
35761  ttttgatacc agaataatac cgtcaatcag gggagtatta ttgaattcat aattaactat
35821  gggtttcatt tttattccat cgacctatcg tgatgcgttc attaccgcca taatcctgaa
35881  aagtcgctat ctgttgataa cccttctcta aaaataggtt tctgacaacg gttccctgtt
35941  tccagccatg ttccagcaat agccatccat ttggtgacag gaaatggcgc gcctgtccca
36001  caattgcctg caaatccgcc atgccatttt gtgcagcgat caatgcagtg gctggttcaa
36061  acctgatatc cccttcttgt agatgaggat cacgctcatc tatatacgga ggattgctga
36121  caatcatatc aaattgttgg ttacccactg ctgcaaacca ctcactttgc aaaaaattca
36181  cattgtgaat ggccagtttt ccggcgtttt tttcagcatt gtgttgtgcc agcatcacgg
36241  catcagagtt gatatcgacc cctgtcacat aacaatcatt ccgctcactt gccaatgcca
36301  gtgcaatcgc ccccgtcccc gtccccagat ccagaatccg ggctggagaa tcaggcaata
36361  attccaatgc cttctccacc agacattcag tatcagggcg cgggatcaac gtcgctggcg
36421  atacggcaaa cggcagtgac cagaattccc gttcaccaat aatataagct accggctctc
36481  cctgaatgcg gcgcaccagc aggctatcaa gctgatgcaa ttcttccgat gagattagcg
36541  tttcatcgaa agcaatcaga taagtacggg aacgccctgt cacgtatccc aacaagattt
36601  ccgcatcacg cttagggctg tcactttcag acaactgggt agccgcatgt tgtagccagc
36661  attggtaatt cattaatcct gctctgacag tgcagacagt tgatctgcct gatattcgat
36721  aatgatcggc tgaataagca tatccagttt gccttctatc acttcatcaa ggcggtataa
36781  cgtcagattg attcggtgat cagtcacacg ccctgtgggg aagttatagg tgcggttgcg
36841  atctgagcgg tcaccagaac ccagcaaatt tcggcgttca gaggcttcca cttcttggcg
36901  cttccgcatc tcagcagcac ggatacgcgc tgccaatacg gacatcgctt ttgctttgtt
36961  tttgtgctgg gaacgctcat cctgacattc cactacgatc cccgttggga gatgggtaat
37021  tcgaatcgca gaatcggtgg tattgacgtg ctgcccaccc gcaccggaag agcgaaacgt
37081  atctatttttc aaatcacccg ggctgatgtc cggtaattca gcttctggaa ttttctggcat
37141  gacagccaca gtacaggcag aagtgtgaat gcgcccctga gattccgttt ccggtacacg
37201  ctggacacga tgaccgcctg attcaaattt caagtgacca taaacctgat cacccgaaac
37261  tttggcaatc acttctttgt agccaccatg ctcgccttcg ttggcgctta taatctctac
37321  tctccagcgg cgggcttccg catagcggct atacatgcgg aacaaatctc ccgcaaatat
37381  cgcggcttca tcgccaccgg ttcctgcccg gacttcaagg aaacagttgc gctcatcatc
37441  cggatctttc ggcaacagca gtagctgtag ctgctgttcc agctcttcat tacgaatttt
37501  tgcctccttg agctcttcct gcgccatttc ccgcatttcg acca
```

## Fig. 2(viii)

Fig. 3

chrim5ed2.seq (37544 bps)

Fig. 4

Fig. 4(cont'd)

A

*Bgl*II-*Bam*HI join   *Not*I join

Xenorhabdus 173 insert

P*L* promoter

AT2 transposon   PLEX
Tpr   Apr

P*L* promoter

B

*Hind*III   *Bam*HI   *Xba*I
*Sph*I   *Hind*III   *Hind*III   *Sph*I

p10-7f**   p13-1f   p14-2f   p20-9r**

p18-7r

2000   4000   6000   8000

Fig. 5

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7   A01N63/00   A01N63/02   C12N15/31   C12P21/00   C07K14/24
//(C12P21/00,C12R1:01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7   A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 22598 A (UNIV READING ;ELAWAD SAMI ABDULRAHAMAN (GB); HAGUE NIGEL GRAHAM MA) 14 May 1999 (1999-05-14) cited in the application page 1 -page 2 page 4, line 7 - line 14 page 5, line 2 - line 8 page 5, line 25 - line 28 page 8, line 1 - line 15; claims 1-3,9,10,14; example 5 -/--	1-9,11, 29

[X] Further documents are listed in the continuation of box C.   [X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
16 May 2000	13/06/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Muellners, W

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X,P	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US AN 2000:109497, GREWAL, PARWINDER S. (1) ET AL: "Allelopathy: A possible mechanism of suppression of plant-parasitic nematodes by entomopathogenic nematodes." retrieved from STN XP002136524 abstract & NEMATOLOGY, (NOV., 1999) VOL. 1, NO. 7-8, PP. 735-743. , ---	1-9,11, 29
X,P	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US AN 2000:109391, HAN, RICHOU ET AL: "Trans - specific nematicidal activity of Photorhabdus luminescens." retrieved from STN XP002136525 abstract & NEMATOLOGY, (NOV., 1999) VOL. 1, NO. 7-8, PP. 687-693. , ---	1-9,11, 29
X,P	CHEMICAL ABSTRACTS, vol. 132, Columbus, Ohio, US; abstract no. 163304, HU, KAIJI ET AL: "Nematicidal metabolites produced by Photorhabdus luminescens (Enterobacteriaceae), bacterial symbiont of entomopathogenic nematodes" XP002136522 abstract & NEMATOLOGY (1999), 1(5), 457-469 , ---	1-9,11, 29
X,P	WO 99 42589 A (NOVARTIS ERFINDUNGEN VERWALTUN ;NOVARTIS AG (CH); KRAMER VANCE CAR) 26 August 1999 (1999-08-26) cited in the application page 1 -page 2, paragraph 3; claims ---	12-18
X	CHEMICAL ABSTRACTS, vol. 126, Columbus, Ohio, US; abstract no. 234686, GEORGIS, R. ET AL: "Novel pesticidal substances from the entomopathogenic nematode-bacterium complex" XP002136523 abstract & ACS SYMP. SER. (1997), 658(PHYTOCHEMICALS FOR PEST CONTROL), 134-143 , ---	1-9,11, 29

-/--

1

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	K. HU ET AL.: "Mortality of Plant-Parastic Nematodes Caused by Bacterial (Xenorhabdus spp. and Photorhabdus Luminescens) Culture Media" JOURNAL OF NEMATOLOGY, vol. 27, no. 4, December 1995 (1995-12), XP000905673 the whole document	1-9,11, 29
X	WO 98 08388 A (MORGAN JAMES ALUN WYNNE ;JARRETT PAUL (GB); ELLIS DEBORAH JUNE (GB) 5 March 1998 (1998-03-05) cited in the application page 1, line 4 - line 9 page 6, line 21 -page 9, line 9 page 11, line 10 -page 12, line 19; claims 17,18,21,23-25,29	6-9, 11-30
X	PATENT ABSTRACTS OF JAPAN vol. 013, no. 286 (C-613), 29 June 1989 (1989-06-29) -& JP 01 080294 A (SUMITOMO CHEM CO LTD;OTHERS: 01), 27 March 1989 (1989-03-27) abstract; figures 2-1	12-18
A	WO 92 19739 A (MYCOGEN CORP) 12 November 1992 (1992-11-12) cited in the application	1-30
X	page 1 -page 2, line 32; claims	12-18

1

INTERNATIONAL SEARCH REPORT

Box I	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

B x II	Observations where unity of Invention Is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest
☐ The additional search fe s were accompanied by th applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9922598	A	14-05-1999	AU	9753098 A	24-05-1999
WO 9942589	A	26-08-1999	AU	3028699 A	06-09-1999
WO 9808388	A	05-03-1998	AU	4024997 A	19-03-1998
			CN	1233938 A	03-11-1999
			EP	0923295 A	23-06-1999
			ZA	9707373 A	15-02-1999
JP 01080294	A	27-03-1989	JP	2117839 C	06-12-1996
			JP	8017707 B	28-02-1996
WO 9219739	A	12-11-1992	AU	667041 B	07-03-1996
			AU	2025292 A	21-12-1992
			AU	656726 B	16-02-1995
			AU	7826491 A	12-12-1991
			BR	9205969 A	26-07-1994
			CA	2042868 A	12-12-1991
			EP	0462721 A	27-12-1991
			EP	0517367 A	09-12-1992
			HU	62928 A	28-06-1993
			JP	4229170 A	18-08-1992
			NZ	242560 A	26-01-1994
			PL	290626 A	24-02-1992
			US	5439881 A	08-08-1995
			US	5753492 A	19-05-1998
			ZA	9203168 A	27-01-1993

PATENT COOPERATION TREATY

PCT

REC'D 2 0 FEB 2001

WIPO   PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference WPP81798	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/GB00/00219	International filing date *(day/month/year)* 24/01/2000	Priority date *(day/month/year)* 22/01/1999

International Patent Classification (IPC) or national classification and IPC
A01N63/00

Applicant

Horticulture Research International et al

---

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 10 sheets, including this cover sheet.

    ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

    These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

    I ☒ Basis of the report

    II ☐ Priority

    III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

    IV ☐ Lack of unity of invention

    V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement

    VI ☒ Certain documents cited

    VII ☒ Certain defects in the international application

    VIII ☒ Certain observations on the international application

---

Date of submission of the demand 16/08/2000	Date of completion of this report 15.02.2001
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Donovan-Beermann, T Telephone No. +49 89 2399 8213

Form PCT/IPEA/409 (cover sheet) (January 1994)

I. Basis f the rep rt

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:

   Description, pages:

   1-47   as originally filed

   Claims, No.:

   1-30   as originally filed

   Drawings, sheets:

   1/14-14/14   as originally filed

2. With regard to the **language,** all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

   These elements were available or furnished to this Authority in the following language: , which is:

   ☐   the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).

   ☐   the language of publication of the international application (under Rule 48.3(b)).

   ☐   the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

   ☐   contained in the international application in written form.

   ☐   filed together with the international application in computer readable form.

   ☐   furnished subsequently to this Authority in written form.

   ☐   furnished subsequently to this Authority in computer readable form.

   ☐   The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

   ☐   The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

   ☐   the description,   pages:

   ☐   the claims,   Nos.:

☐ the drawings,   sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	
	No:	Claims	1-30
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-30
Industrial applicability (IA)	Yes:	Claims	6-30
	No:	Claims	

2. Citations and explanations
   see separate sheet

VI.   Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

   see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

Ad Section V:

The present application relates to the control of nematodes using bacteria. The bacteria are symbionts of entomopathogenic nematodes. The bacteria or agents derived from them may be used as the control agents; alternatively engineered bacteria or agents derived from them are used to control nematodes. The nematode to be controlled is normally different from that with which the bacteria is symbiotically associated. Particular bacteria used are *Xenorhabdus* strains such as *Xenorhabdus bovenii.* *Photorhabdus* is also mentioned as a typical species suitable.

WO-A-9922598 (D1, cited in the application) (see section VI below), although published between the priority date and the international filing date of the present application, is considered prior art for the present case in as far as the presently claimed priority is not valid for substantial parts of the present application. The applicant has added subject matter in filing the PCT application, which was not present in the priority filing. For that subject matter of the present application which thus has the date 24.01.00, D1 is relevant to Art.33 PCT as being prior art according to Rules 33 and 64 PCT. It may in the EP procedure become relevant to the complete present application under Art.54(3) EPC, since D1 has a filing date before the priority date of the present application.

D1 discloses biopesticide compositions for the control of insect pests and/or plant-parasitic nematodes, which use bacteria known to be symbionts of nematodes (see page 4, line 11-page 5, line 8). The bacteria species is eg. *Xenorhabdus bovenii* (see page 5, lines 25-28).

In the present application, the priority document claims the use of and compositions containing *Xenorhabdus* strain C42 but not the strains of *Xenorhabdus bovenii.* Thus the disclosure of D1 is prejudicial to novelty of the present claims in as far as they relate to this added subject matter. The presently claimed *Xenorhabdus bovenii* have the same activity as those of D1, and at present no distinction is seen. If the presently claimed strains could be proven to be novel over those of D1, it is still considered that in the light of the disclosure of D1, it would be obvious to the skilled person to seek other strains of *Xenorhabdus bovenii* which could be useful as nematocides. Thus the

subject matter of claims 9 and 10 is neither novel nor inventive (Art.33(2) and (3) PCT).

Nematology, November 1999, Vol.1(7-8), pp 735-743 (D2), is published between the priority date and the international filing date of the present application and is considered prior art for the present case in as far as the presently claimed priority is not valid for substantial parts of the present application. D2 discloses that symbiotic bacteria of entomopathogenic nematodes were able to suppress plant-parasitic nematodes. Cell-free culture filtrates from *Xenorhabdus bovenii* were effective (see Figs.3 and 4). Similar arguments apply as for D1 above, since clearly the strains of *Xenorhabdus bovenii* used in D2 are pathogenic to plant-parasitic nematodes. Thus the subject matter of claims 9 and 10 is not novel.

Nematology, November 1999, Vol.1(7-8), pp 687-693 (D3) and Nematology, 1999, Vol.1(5), pp 457-469 (D4) relate to subject matter that is fully priority-supported, and are thus of no further relevance to this application.

WO-A-9942589 (D5, cited in the application) (see section VI below), published between the priority date and the international filing date of the present application, is considered prior art for the present case in as far as the presently claimed priority is not valid for substantial parts of the present application. D5, like D1 above, may in the EP procedure become relevant to the complete present application under Art.54(3) EPC, since D5 has priority dates before the priority date of the present application.

D5 discloses nucleic acid sequences from *Photorhabdus luminescens*, which encode toxins (amino acid sequences) having insecticidal activity (see pages 1-3). Activity against plant-parasitic nematodes is not described. However, the activity described in D5 has no bearing on the fact that in the present application, claim 6 encompasses compositions containing such agents as those of D5. Indeed, on page 13 of the present application, the applicant himself states that the agents of D5, D1 etc. are useful in the present invention. The subject matter of claims 6, 7, 11-18 thus cannot be acknowledged as being novel (Art.33(2) PCT). D5 discloses recombinant vectors comprising the nucleic acid sequences and their inclusion into host cells (see paragraph bridging page 16-17). Thus the subject matter of claims 24-29 is also not novel. The probes claimed in claim 19 are parts of the nucleic acids known from D5 and

are thus also not novel. Methods for identifying or cloning known nucleic acids cannot be recognised as novel, since such methods are also used in D5 (claims 20-23).

American Chemical Society Symposium Series, 1997, Vol.658(Phytochemicals for pest control), pp 134-143 (D6) discusses the potential for using symbiotic bacteria of nematodes such as *Xenorhabdus* and/or their metabolites to control plant-parasitic nematodes (see pages 138-141). Thus the subject matter of claims 1-8 is neither novel nor inventive.

Journal of Nematology, 1995, Vol.27(4), pp 502-503 (D7) discloses the use of cell-free culture filtrates of *Xenorhabdus bovenii* effective against nematodes. As for D2, one must presume that the strains themselves were effective. Thus the subject matter of claims 1-9 is neither novel nor inventive. The subject matter of claim 10 cannot be considered to be inventive with regard to D7, since it would be obvious to the skilled person to look for alternative stains of such bacteria, with the same or similar activity against nematodes.

WO-A-9808388 (D8, cited in the application) discloses pesticidal methods and compositions derived from *Xenorhabdus* (see page 1, lines 4-9 and page 2, line 29-page 3, line 34). Nucleic acids which code for toxins in the bacteria are described. The toxins are proteins (see page 6, line 21-page 9, line 9). Methods for identifying such proteins, probes therefor, host cells transformed to express the proteins etc. are all described (see also page 11, line 10-page 12, line 19). Thus the subject matter of claims 6-8 and 11-30 is not novel.

JP-A-01080294 (D9) discloses insecticidal proteins from *Bacillus thuringiensis*, which would appear to be prejudicial to novelty of claims 12-18.

WO-A-9219739 (D10, cited in the application) discloses nematocidal toxins and genes coding for them, which are derived from *Bacillus thuringiensis* (see pages 1 and 2 and claims). This disclosure is thus prejudicial to novelty and inventive step of claims 12-18 (see also note on scope of claim 6 in section VIII).

WO-A-9717432 (D11, cited in the application but not in the International Search Report)

discloses, like D5 and D8, insecticidal toxins from *Photorhabdus luminescens*, and forms the basis for similar objections.

For the assessment of the present claims 1-5 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Claims 1-5 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Ad Section VI:

The following documents were published after the priority/filing date of the present application but have priority/filing dates prior to those of the present application. These documents may therefore be relevant to patentability of the presently claimed subject matter:

Certain published documents (Rule 70.10)

Application No Patent No	Publication date *(day/month/year)*	Filing date *(day/month/year)*	Priority date *(valid claim)* *(day/month/year)*
WO-A-9922598	14.05.99	30.10.98	30.10.97
"	"	"	03.11.97
WP-A-9942589	26.08.99	18.02.99	20.02.98
"	"	"	20.01.99

Ad Section VII:

The certificate of deposit for *Xenorhabdus* strain X42 seems to be absent from the file.

The dependency of claim 11 does not make grammatical sense and should thus be corrected.

Ad Section VIII:

In claim 6, the composition is specified to contain "a species of bacterium which is a symbiont of an entomopathogenic nematode, or an engineered bacterium, or a nematode control agent derived from a natural or engineered bacterium."

Firstly, the definition of "a species of bacterium which is a symbiont of an entomopathogenic nematode" could cover a multitude of known bacteria which were however not yet known to be nematocidal. Compositions containing such bacteria cannot be accorded novelty by virtue of a new use (see section V above).

Secondly, in the present wording of the claim, the " engineered bacterium, or a nematode control agent derived from a natural or engineered bacterium" are not subject to the same definition of being derived from bacteria which are symbionts of entomopathogenic nematode, which is seen to be the central idea of the application. This subject matter is thus either vague, or non-unitary, depending on how one looks at it. In either case, it is objected to, under both Art.6 PCT and Rule 13 PCT. Claim 11 is also subject to this objection as far as the "engineered bacterium" is concerned.

The subject matter of claim 11 and therefore also the claims dependent upon it is not considered to be clear in scope as required by Art.6 PCT. The skilled person would have considerable difficulty in determining what subject matter actually falls within the scope of the present wording. The use of the phrasing "functional activity against a nematode" is too unspecific, and appear to express a desired effect rather than the concrete product.

In claim 13, similar objections apply as for claim 11. The applicant has not found such

"degeneratively equivalent sequence" or "functional variant thereof", thus this subject matter, in any case vague, appears again to be wishful thinking on his part. The skilled person would have considerable difficulty in determining the scope of this claim.

Claim 19 is also considered to be unclear in its scope (Art.6 PCT). No further definition is put on the sequence than that it has at least 15 nucleotides, and is part of nucleic acids according to claims 12 to 18 (which are presently unclear in scope). Even if claims 12 to 18 were clearly defined, the number of shorter sequences defined by this claim would seem to be rather large, and the risk of accidental overlap with prior art also rather high. Without knowing what is encompassed by the claim, not only is it unclear, but no proper assessment of novelty can be made.

In claim 30, the "or fragment thereof" qualification to the antibody, brings the claim scope into doubt.

The patent documents listed on page 13 to which the phrase "the disclosures of which are incorporated by reference" refers, do not appear to be essential to the performance of the invention as required by Article 5 PCT. Thus this phrase should be deleted unless any of the subject matter is indeed considered to be essential; in which case it should be incorporated expressly in the description (see PCT Guidelines C-II, 4.17).